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The use of antibiotics and antimicrobial drugs has pl yed a large role in the elimination of many 
infectious diseases, however the wide spread use of uch drugs has given rise to the phenomenon 
of antimicrobial resistance and has rendered antibiotics ineffective to a broad range of bacteria. 
The aim of the study was to ascertain the differences if any in the phenotypic and genotypic 
resistance profiles of K. pneumoniae isolated from a single tertiary hospital in two surveillance 
studies undertaken at different times, viz., 2001 and 2007 with special emphasis on ESBLs.  A 
correlation with antibiotic use was also undertaken. 
ESBL positives were identified and phenotypic resistance profiles were generated based on the 
resistance profiles of individual isolates by means of their MIC data.  The molecular detection of 
ESBLs was carried out using representative isolates nd sequencing was based on the phenotypic 
expression of the most common ESBL genes. The data w s summarized using median values and 
interquartile ranges.  Antibiotic use and susceptibility in 2000 was compared to that in 2007 using 
a Wilcoxon signed rank test for paired data since the same drugs were tested in both years. 
Of the isolates that were tested, sequencing reveald that TEM – 1 was identified in all isolates 
and SHV-1 and SHV-2 were identified in 60 % in the isolates collected in 2000 and 77 % and 11 
% respectively in the isolates collected in 2007. SHV – 11 was present in 67% of isolates from 
2007 and 55% of those were in combination with SHV – 1. Sequencing also revealed CTXM-15 
present in one of the isolates collected in 2007. There was 100% susceptibility to cefoxitin and 
only one isolate in 2007 showing an intermediate result to imipenem.  
No novel β-lactamases were identified in this study; however th  decrease in susceptibility over 
time is proof of bacterial evolution.  The variety of β-lactamases and diversity of plasmid profiles 
in these two small populations provides proof to the claim that dissemination of resistance in 
Klebsiella pneumonia is effortless. Statistical analysis showed an increase in resistance from the 
year 2000 to 2007 however the correlation between overall antibiotic use and the increase in 
resistance did not reach statistical significance. It was observed that resistance increased despite 
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INTRODUCTION AND LITERATURE REVIEW 
 
1.1 Resistance and its impact 
  
Ever since antibiotics and other antimicrobial drugs first became widely used in the World War II 
era, they have saved countless lives and eliminated serious complications in many diseases and 
infections (NIAID, 2006).  Antimicrobials are said to be modern medicines greatest achievement. 
Subsequent to the advent of antimicrobials however, many of them have not sustained the power 
they initially were thought to possess and many of them have become ineffective. 
 
Over time, the widespread use of antibiotics has result d in extensive evolutionary adaptations in 
bacteria that enabled them to survive these powerful dr gs (NIAID, 2006) Antimicrobial 
resistance has facilitated the survival of microbes and hence the battle against disease and 
infection is becoming alarmingly difficult to win.  Antibiotic resistance is comparable to survival 
of the fittest, where the increased prevalence of resistance is as a result of evolution.  Infectious 
organisms have the ability to adapt very rapidly to new environmental conditions and just a single 
random genetic mutation can facilitate bacterial evolution (Philippon, Arlet and Jacoby, 2002). 
 
It is increasingly evident that resistance has become a problem with all categories of antibiotics 
and is especially so in the β-lactam antibiotics which include but are not limited to penicillin, 
penicillin derivatives, cephalosporins, carbapenems, cephamycins, carbecephems and the 
monobactams.  The β-lactam group of antibiotics is by far the largest group of antibacterial 
agents used in clinical medicine. Their structure is based on the four-membered nitrogen-
containing β-lactam ring that gives them the antibacterial activity (Duerden, 1987).  The β-lactam 
antibiotics have structural similarities with the binding sites of bacterial substrates which enable 
them to attach to and inactivate the transpeptidases involved in bacterial cell wall synthesis 
(Williams, 1999).   
 
The three primary mechanisms of  beta-lactam antibiotic resistance are: i) alterations to the 
structure of the antibiotic target site, ii) changes that prevent access of an adequate concentration 
of the antibiotic  to the active site, and,  most commonly and most importantly, iii) enzymatic 





may result in the inability of the antibiotic to bind to its target. β-lactam antibiotics bind to 
penicillin binding proteins (PBPs) and a change in the active site of PBPs can lower the affinity 
of β-lactam antibiotics therefore increasing resistance to these agents (Drawz and Bonomo, 
2010).  Preventing the access of an antibiotic to its target is a resistance strategy as a result of a 
permeability barrier or the presence of an efflux pm  mechanism (Mulvey and Simor, 2009).  In 
order to access PBPs on the inner plasma membrane β-lactam antibiotics must either diffuse 
through or directly cross porin channels on the outside of the bacterial cell wall. Point mutations 
or insertion sequences in porin-encoding genes can produce proteins with decreased function, 
either a change in the porin channel size or the regulation of opening and closing of porins which 
lowers the permeability to β-lactams. Some organisms have evolved to express an active efflux 
mechanism that exports the antibiotics from the cytoplasm before allowing any binding to occur 
(Drawz and Bonomo, 2010). 
 
Bacteria may produce enzymes that modify or destroy the chemical structure of an antibiotic 
rendering it inactive. In the case of β-lactam antibiotics, the most effective way for bacteria to 
counteract the effect of these antibiotics has been by producing β-lactamases which are enzymes 
that inactivate the antibiotics by hydrolyzing the β-lactam ring (Kong, Schneper and Mathee, 
2010).  β-lactamases were thought to have evolved from penicilli  binding proteins and the first 
plasmid mediated β-lactamase, TEM-1 was discovered in the early 1960’s (Bradford, 2001).  
Other β-lactamases were soon discovered which conferred resistance to the extended spectrum 
cephalosporins hence these new β-lactamases were named extended-spectrum β-lactamases 
(Paterson and Bonomo, 2005).    Extended-spectrum β-lactamases (ESBLs) are those β-
lactamases that are capable of conferring bacterial r sistance to the penicillins, first-, second- and
third-generation cephalosporins and aztreonam  and are inhibited by β-lactamase inhibitors such 
as clavulanic acid (Rawat and Nair, 2010). Many new β-lactam antibiotics have been developed 
that were specifically designed to be resistant to the hydrolytic action of β-lactamases.  However 
with each new class, new β-lactamases have emerged causing resistance to that class of drug 
(Bradford, 2001). 
 
More than a thousand unique protein sequences for β-lactamases have been identified and more 
are discovered yearly (Malloy and Campos, 2011).  The classification of β-latamases involve two 
major approaches: the first one called the Bush-Jacoby-Medeiros classification scheme is based 
on the similarities in the functional characteristic  of the enzyme while the second approach, the 





Schneper and Mathee, 2010).  The Bush-Jacoby-Medeiros classification scheme is comprised of 
four groups and subgroups in which the ESBLs  belong to group 2be or 2d (Rawat and Nair, 
2010) The molecular classification of β-lactamases is based on the nucleotide and the protin 
sequences in these enzymes. The β-lactamases under this classification are divided into four 
groups or molecular classes, A, B, C and D. Classes A, C and D include enzymes that hydrolyze 
their substrates by forming an acyl enzyme through an active site serine whereas class B β-
lactamases make use of an active site zinc ion to facilitate hydrolysis (Bush and Jacoby, 2010). 
 
Antibiotic resistance may either be intrinsic or acquired. Intrinsic resistance is straightforward to 
treat because intrinsic mechanisms are those specified by naturally occurring genes found on the 
host’s chromosomes (Alekshun and Levy, 2007). Acquired resistance may occur in two ways: by 
mutation which is a random event or by the transfer o  resistance determinants borne on mobile 
genetic material including but not limited to plasmids, bacteriophages, transposons, integrons, 
gene cassettes and insertion sequences (Table 1.1). The process of gene transfer that disseminates 
information is accomplished by transformation, conjugation and transduction. Transformation is 
the transfer of naked DNA following bacterial cell death into receptive bacterium (Barker, 1999).  
 
Conjugation is horizontal gene transfer by cell to cell contact. Plasmids are mobile genetic 
elements, which are extra-chromosomal DNA that transfer horizontally within and across bacteria 
via conjugation. Plasmids can also serve as vehicles for transposons and integrons therefore 
through plasmid conjugation bacteria are exposed to an extensive number of genes from the 
mobile gene pool. (Williams and Hergenrother, 2008).  Transduction is the transfer of DNA from 
one cell to another mediated by a bacteriophage. It occurs as a consequence of rare errors in 
phage reproduction when a small percentage of phage p rticles that are produced contain DNA 













Abbreviations: Bleo, bleomycin; Kan, kanamycin; Mino, minocycline; Spc, spectinomycin; Str, 





Table 1.1 Mobile Genetic Elements ( Alekshun and Levy, 2007) 
Genetic element General characteristics Resistance determinants(s) 
   
Plasmid 
Variable size (1 - >100kb), 
conjugative and mobilizable 
R Factor, multiple resistances 
   
Insertion Sequence 
Small (2kb), contains 
terminal inverted repeats, and 
specifies a transposase 
IS1, IS3, IS4 etc. 
   
Composite (compound) 
Flanked by insertion 
sequences and /or inverted 
repeats 
Tn5: Kan, Bleo and Str 
   
Complex transposon 
Large (>5kb), flanked by 
short terminal inverted 
repeats, and specifies a 
transposase and recombinase 
Tn1 and Tn3: β-lactamase 
Tn7: Tmp, Str, Spc Tn1546: 
glycopeptides 
   
Conjugative transposon Promotes self transfer Tn916: Tet and Mino 
   
Transposable bacteriophage 
A bacterial virus that can 
insert into the chromosome 
Mutation 
   
Integron 
Facilitates acquisition and 
dissemination of gene 
cassettes, specifies an 
integrase, attachment sites, 
and transcriptional elements 
to drive the expression of 
Class 1: Multiple single 
determinants and MDR Class 
2: (Tn7) Class 3: 
Carbapenems Class 4: Vibrio 





1.2 β-Lactam Antibiotics  
 
1.2.1 β-Lactam antibiotic mechanism of action 
 
β-lactams are among the classes of antibiotics that interfere with specific steps in homeostatic cell 
wall biosynthesis. Successful treatment with a cell wall synthesis inhibitor can result in changes 
to cell shape and size, induce cellular stress responses, and result in cell lysis (Kohanski, Dwyer 
and Collins, 2010). Bacteria rely on a heavily cross-linked peptidoglycan layer for the 
preservation of cell shape and rigidity. This peptidoglycan layer is comprised of a repeating unit 
of an alternate disaccharide, N-acetyl glucosamine (NAG) and N-acetyl muramic acid (NAM) 
(Wilke, Lovering and Strynadka, 2005).   A pentapeptide is attached to each NAM unit, and the 
cross-linking of two D-alanine–D-alanine NAM pentapeptides is catalyzed by PBPs, which act as 
transpeptidases (Drawz and Bonomo, 2010).   
 
β-lactams inhibit the transpeptidation precisely in the last stage of the synthesis of the cell wall. 
For β -lactams to act, it is necessary for the bacteria to be in the multiplication phase, which is 
when the cell wall is synthesized (Mar and Francesc, 2003) The β-lactam ring is stereochemically  
similar to the D-alanine–Dalanine of the NAM pentapeptide, and PBPs incorrectly use the β -
lactam as a “building block” during cell wall synthesis. This results in acylation of the PBP, 
which renders the enzyme unable to catalyze further ranspeptidation reactions. As cell wall 
synthesis slows to a halt, peptidoglycan autolysis continues (Fig 1.1). This results in weakly 
cross-linked peptidoglycan, which makes the growing bacteria highly susceptible to cell lysis and 






























Fig 1.1 Schematic representation of antibiotic mechanism of action illustrating the breaking of the 
cross-linked peptidoglycan bridge (Depardieu et al., 2007) 
 
After 70 years of clinical use, which began with the administration of penicillin to a patient with 
staphylococcal sepsis in 1941, β -lactam antibiotics have become frequently prescribed. The 
continual rise of resistance and the progress in understanding its molecular mechanisms has 
further augmented interest and has led us to discover the wealth of information on each 
component of this family of antibiotics (Mar and Francesc, 2003).  They all have a β lactam ring, 
which can be hydrolyzed by β-lactamases. The groups differ from each other by additional rings, 
e.g. thiazolidine ring for penicillins, cephem nucleus for cephalosporins, none for monobactams 




In 1921,  Alexander Fleming a Scottish bacteriologist, suffering from a common cold, inoculated 
agar plates with his own nasal secretion to determine the change of his nasal bacteria.  No 
colonies appeared for several days. This suggested the presence of a substance that affected the 
ability of bacteria to grow. The substance, initially named lysozyme was found to be very 
effective causing cell wall lysis in many Gram-positive bacteria. (Kong, Schneper and Mathee, 





produced a substance that inhibited the growth of Staphylococcus aureus and this substance was 
so named penicillin (Henderson, 1997).  Due to the difficulties of production and purification, 
penicillin was not used in the treatment of infections until 1941 where penicillin was produced in 
sufficient quantities to conduct clinical trials (Wright, 1999).   
 
Penicillins contain a β-lactam ring and a thiazolidine ring to form 6-aminopenicillanic acid 
creating the characteristic double ring (Figure 1.2). They also have a side chain, which varies 
among penicillins, in position 6 of the β-lactam ring and that is what defines their properties (Mar 
and Franchesc, 2003).The β-lactam nucleus, 6-aminopenicillanic acid 6-APA proved to be the 
key in penicillin synthesis and modification. Thereaft r, semi-synthetic β-lactam compounds have 
been developed continuously and systematically (Kong, Schneper and Mathee, 2010).   
 
Natural penicillins were the first agents in the penicillin family to be introduced for clinical use. 
Benzylpenicillin, or Penicillin G are the parent drugs of this family and have been used 
extensively. The natural penicillins proved to be initially very successful and it was this success 
that led to the development of the penicillinase-resistance penicillins; methicillin, oxacillin, 
nafcillin, dicloxacillin, cloxacillin and flucloxacillin (Wright, 1999).  Methicillin was the first 
semi-synthetic penicillin to be introduced into clinical use then followed the replacement of 
methicillin by nafcillin and oxacillin as it was found that these two penicillins were similar in 
their effectiveness (Wright, 1999). 
 
Further manipulation of the basic penicillin structure introduced penicillins which had an 
extended activity against gram-negative bacilli. These are the aminopenicillins, 
carboxypenicillins and ureidopenicillins. Aminopenicill ns are water soluble and pass through 
porin channels in the cell walls of some gram negative organisms (Gallagher and MacDougall, 
2011).  This group of penicillins has a broader antibacterial spectrum because they have a better 
capacity to penetrate the porins of gram negative bacteria (Mascaretti, 2003).  Extended spectrum 
penicillins were developed with the goal of treating infections caused by Pseudomonas 
aeruginosa, and include the carboxypenicillins and the ureidopenicillins (Chevez-Bueno and 
Stull, 2009).  
 
The carboxypenicillins consist of carbenicillin and ticarcillin; the substitution of a carboxyl group 
for the amino group on ampicillin produces carbenicillinand the subsequent substitution on the 





are not very active against enterococci because of po r binding to their PBPs (Chevez-Bueno and 
Stull, 2009).  The ureidopenicillins are semisynthetic derived from the ampicillin molecule with 
acyl side chain adaptations. They have enhanced aerobic gram-negative activity including anti-
pseudomonal activity. Included in this group are mezlocillin, azlocillin and piperacillin (Chevez-
Bueno and Stull, 2009).  Their enhanced activity over other penicillins is attributed to their 
structure which allows greater penetration of the cell wall and the increased affinity to PBPs 
(Wright, 1999). Due to the structure of penicillins and the ability to adapt their side chains, it has





















Figure 1.2 Chemical structure of the various penicillins found in this family. 1 – Benzyl penicillin 
(a – β-lactam ring, b – Thiazolidine ring, c – variable side chain), 2- Methicillin, 3- Ampicillin, 4 










The cephalosporin ring structure is derived from 7-aminocephalosporanic acid.  Cephalosporins 
contain the basic beta-lactam ring but the cephalosporin structure allows for more gram negative 
activity than the penicillins (Duerden, 1987).  Penicillins and cephalosporins have the same four-
member beta-lactam ring, but cephalosporins have an additional atom in the side ring. (Harrison 
and Bratcher, 2008).  The cephalosporin basic structure consists of a cephem nucleus, which 
consists of a dihydrothiazine ring instead of the tiazolidine ring characteristic of penicillins. 
Specific modifications in the acyl side chains result in different cephalosporins (Figure 1.3.2), 
(Mar and Franchesc, 2003). Most cephalosporins are broad-spectrum compounds, affecting both 
Gram positive and Gram negative bacteria; however major differences in their spectra exist. 
(Livermore and Williams, 1996). 
Cephalosporins are classified by generation.  Lower-generation cephalosporins have more gram-
positive activity and higher-generation cephalosporins have more gram-negative activity. The 
fourth generation drug cefepime is the exception to the rule due to the gram-positive activity 
being equivalent to first-generation and gram-negative activity equivalent to third-generation 
cephalosporins. Individual cephalosporins in the higher generations have differentiating 
properties that may warrant specific indications (Harrison and Bratcher, 2008). 
 
The first generation cephalosporins are moderate spectrum agents, with a spectrum of activity that 
includes penicillinase-producing, methicillin-susceptible staphylococci and streptococci.   The 
first two cephalosporins to be introduced into clini al practice were cephalothin and cephaloridine 
(Duerden, 1987).  The intrinsic activity of cephalosp rins in the first generation against Gram-
positive cocci is similar to that of benzylpenicillin and is sustained against producers of β-
lactamases (Livermore and Williams, 1996).  
 
 The second generation cephalosporins have a greater Gram-negative spectrum while retaining 
some activity against Gram-positive cocci. Because of greater stability against beta-lactamases, 
enhanced activity occurs among second-generation cephalosporins (Harrison and Bratcher, 2008).  
The second-generation cephalosporins include but are not limited to cefamandole, cefonicid, 
ceforanide, and cefuroxime. Although cefoxitin, cefot tan, and cefmetazole are also included in 
this class, these agents are technically considered cephamycins because of their methoxy side 





These antibiotics are usually active against the same organisms as the first-generation 
cephalosporins, but they have more activity against certain aerobic Gram-negative bacteria and 
Haemophilus influenzae (Kalman and Barriere, 1990)   
 
Third generation cephalosporins have a broad spectrum of activity and further increased activity 
against Gram-negative organisms. Some members of this group have decreased activity against 
Gram-positive organisms (Mandell, 1990). Two of the oral third generation cephalosporins, 
cefixime and ceftibuten have an advantage over the o r oral cephalosporins because of their 
greater β-lactamase stability and their Gram negative coverag .  Cefexime however has poor 
activity against staphylococci and is only marginally ctive against pneumococci (Harrison and 
Bratcher, 2008). The parenteral 3rd-generation cephalosporins are generally less active against 
staphylococci and susceptible to first generation cephalosporins, but they have an expanded 
spectrum of activity against Gram negative bacteria (Kalman, 1990). 
 
Fourth generation cephalosporins are extended-spectrum agents with similar activity against 
Gram-positive organisms as first-generation cephalosporins. They have a greater resistance to 
beta-lactamases than the third generation cephalosporin . They are also used against 














Fig 1.3. Representative structure of Cephalosporin illustrating the common β-lactam ring, a 
feature shared with the Penicillins, the Dihydrothiazine ring and the Acyl side chain which may 







The carbapenems are β-lactam antimicrobial agents with an exceptionally broad spectrum of 
activity.  Carbapenems are stable to most β-lactamases including AmpC beta-lactamases and the 
extended-spectrum beta-lactamases. These drugs continue to be one of the most active classes of 
antibiotics against many resistant pathogens. (Zhanel et al., 2007). Carbapenems are related to 
penicillin (penam) and cephalosporin (cephem). They differ from the penams by the presence of a 
carbon at position 1 instead of a sulphur, and unsat ration in the 5-membered ring (Devasahayam 
et al., 2011).   Among the many different structurally distinc  classes of β-lactams, the 
carbapenem class is considered to be the most potent and to have the widest spectrum of 
antimicrobial activity (Shah, 2008).  
 
Carbapenems are capable of passing through porins in outer wall of Gram negative bacteria and 
have a high affinity to PBPs. This class of antibiotics consist of imipenem, meropenem ertapenem 
and doripenem whose broad spectrum of activity includes activity against many Gram-positive, 
Gram-negative and anaerobic bacteria (Zhanel et a ., 2007).  Imipenem (Fig 1.4) was licensed in 
1984 in Germany. It was more than 10 years before a s cond carbapenem, meropenem (Fig 1.4), 
was licensed in 1995, while ertapenem (Fig 1.4) waslicensed by the European Community in 
2002 (Shah, 2008). Doripenem, the newest addition to this family of antibiotics is a synthetic 
antibiotic that is structurally related to β-lactam antibiotics. This compound is stable in the
presence of β-lactamases and is resistant to inactivation by renal dehydropeptidases. Doripenem, 
like the other carbapenems, inhibits bacterial cell wa l synthesis by inactivating essential PBPs, 
ultimately causing cell death (Greer, 2008). It is probable that due to the activity of these drugs 















Fig 1.4 Carbepenems: Imipenem, Meropenem and Ertapenem illustrating the characteristic β-
lactam ring (circled) and the carbon in the five-membered ring in place of the sulphur in the 
cephalosporins and the penicillins (Shah and Isaacs, 2003). 
 
1.3 β-Lactamase inhibitors 
 
 β-Lactamase inhibitors are structurally related to penicillin, retaining the amide bond of the β-
lactam group of the parent compound, but with a modified side chain (Figure 1.5). The three 
Class A β-lactamase inhibitors clinically used; are clavulanic acid, sulbactam and tazobactam 
(Babic, Hujer and Bonomo, 2006). These three beta-lactamase inhibitors, acting like β-lactams, 
bind to the active site of β-lactamases but fail to be efficiently hydrolyzed. Instead, they undergo 
“inactivation kinetics” in which the acyl-enzyme complex is either hydrolyzed very slowly and 
produce chemical changes that allow irreversible binding to the enzyme (Perez-Llarena and Bou, 
2009).  Carbapenems, monobactams and cephalosporins have shown inhibition activity against 
class C β-lactamases and even selectively class A β-lactamases, however their selection for 
inhibition coupled with increasing resistance among them do not technically render these β-






Fig 1.5 Chemical structure of Class A β-Lactamase inhibitors. All members have the 
characteristic β-Lactam ring with modified side chains (Perez-Llana d Bou, 2009). 
 
1.3.1 Clavulanic acid 
 
Clavulanic acid inhibits many molecular class A β-lactamases, including staphylococcal 
penicillinases, the most prevalent plasmid-mediated β-lactamases of Gram-negative rods, and the 
chromosomal enzymes from Bacteroides fragilis, Proteus vulgaris, and Citrobacter diversus 
(Livermore and Williams, 1996). Clavulanic acid was the first β-lactamase inhibitor introduced 
into clinical medicine and was isolated from Streptomyces clavuligerus in the 1970s. Clavulanate 
showed little antimicrobial activity alone, but when combined with amoxicillin, clavulanate 
significantly lowered the amoxicillin MICs against S aphylococcus aureus, K. pneumoniae, 
Proteus mirabilis, and Escherichia coli (Drawz and Bonomo, 2010). 
 
Clavulanic acid thus has inconsequential intrinsic antimicrobial activity, despite sharing the β-
lactam ring that is characteristic of beta-lactam antibiotics. Clavulanic acid lacks the side chain 
bound to the C-6 atom that is characteristic of β-lactam antibiotics, and it also has an exocyclic 
substituent attached to the C-2 atom (Perez-Llana and Bou, 2009). The similarity in chemical 
structure, however, allows the molecule to act as a competitive inhibitor of beta-lactamases 
secreted by certain bacteria to confer resistance to b ta-lactam antibiotics. This inhibition restores 
the antimicrobial activity of beta-lactam antibiotics against β-lactamase-secreting resistant 












In 1978, Pfizer laboratories synthesised the penicillanic acid sulphone known as sulbactam. This 
represents an important difference with respect to lavulanic acid, as the former was obtained by 
semi-synthesis. This compound shows very good beta-lac mase-inhibitory activity, mainly 
against class A beta-lactamases (Perez-Llana and Bou, 2009).  Sulbactam is an irreversible 
inhibitor of beta-lactamase; it binds the enzyme and does not allow it to interact with the 
antibiotic. Sulbactam is able to inhibit the most common forms of beta-lactamase but is not able 
to interact with the ampC cephalosporinase. Thus, it confers little protection against bacteria such 
as Pseudomonas aeruginosa, Citrobacter, Enterobacter, and Serratia, which often express this 




Tazobactam was reported in 1987, it was also obtained via semi-synthesis as an inhibitor with 
good affinity to most class A and some class D beta-lactamases and with moderate affinity to 
class C β-lactamases (Perez-Llana and Bou, 2009).  Its mechanism of action is very similar to that 
of clavulanic acid and sulbactam which can act either reversibly or transiently (Drawz and 
Bonomo, 2010). It is a compound which inhibits the action of bacterial β-lactamases. It broadens 
the spectrum of piperacillin by making it effective against organisms that express β-lactamase and 
would normally degrade piperacillin.  Tazobactam sodium is a derivative of the penicillin nucleus 
and is also a penicillanic acid sulfone (James and Gurk-Turner, 2001). 
 
1.4 β-Lactamases  
 
β-lactamases are among the most heterogeneous group of resistance enzymes. The number of 
unique protein sequences for β-lactamases have exceeded 1000 (K. Bush and G. Jacoby, 
http://www.lahey.org/Studies/ , 2012. These globular proteins are composed of alpha–helices and 
beta–pleated sheets. Two systems are commonly used to classify β -lactamases: the Ambler 
scheme and the Bush- Jacoby-Medeiros scheme as summarized in Table 1.2. Both of these 
classification schemes are used interchangeably in the literature. (Perez et al., 2007). 
 
As previously mentioned extended spectrum beta lactamases or ESBLs are those β-lactamases 





unique challenges to researchers and clinicians since these ESBLs are enzymes that are capable of 
hydrolyzing penicillins, broad-spectrum cephalosporins and monobactams (Rupp, 2003).  Class A 
and C β-lactamases are the most common and have a serine rsidue at the active site as do class D 
β-lactamases.  Class B compromises the metallo β- actamases (Jacoby, 2005). Classes A, C and 
D share a similar fold (Figure 1.6) and all have a mechanism that involves creation of a serine 
nucleophile by de-protonation of an active site serine with a general base, nucleophilic attack of 
the β-lactam ring to form an acyl-enzyme intermediate, and hydrolysis of the intermediate using a 



















Fig 1.6 Schematic representation of Class A, B, C and D β-lactamases illustrating the fold 
structures of these β-lactamases (Drawz and Bonomo, 2010). 
 
Ambler Class A enzymes (Bush Group 2) are penicillinases that are susceptible to beta-lactamase 
inhibitors. The TEM-1 and SHV-1, the extended spectrum beta-lactamase precursors in group 2b, 
are the beta-lactamases usually found in Escherichia coli and K. pneumoniae that confer 










The first plasmid-mediated β-lactamase in Gram-negative bacteria, TEM-1 was described in 
the early 1960s. It was so designated because it was isolated from the blood culture of a 
patient named Temoniera in Greece (Rawat and Nair, 2010). The SHV, β-lactamase found 
primarily in K. pneumoniae, was named from the term “sulfhydryl reagent variable”, was 
discovered shortly after (Drawz and Bonomo, 2010). Subgroup 2b β-lactamases readily 
hydrolyze penicillins and early cephalosporins, such as cephaloridine and cephalothin, and are 
strongly inhibited by clavulanic acid and tazobactam. They include the TEM-1, TEM-2 and 
SHV-1 enzymes (Bush and Jacoby, 2010). Subgroup 2 be comprises ESBLs, ‘e’ denoting 
extended (Table 1.2). These broad-spectrum enzymes retain the activity against penicillins 
and cephalosporins of subgroup 2b β-lactamases and in addition hydrolyze one or more 
oxyimino- β-lactams, such as cefotaxime, ceftazidime, and aztreonam. The first and largest 
subset of subgroup 2be was derived by amino acid substit tions in TEM-1, TEM-2, and SHV-
1 that broadened their substrate spectrum (Bush and J coby, 2010). As with TEM, SHV-type 
ESBLs have one or more amino acid substitutions around the active site (Jacoby, 2005). More 
than 150 varieties of SHV are currently recognized on the basis of unique combinations of 
amino acid replacements.  
 
The third largest group of ESBLs after the TEM and SHV groups is the CTX – M enzymes. 
Based on sequence homology, these are divided into five subgroups with around 40 members. 
Most of these subgroups have evolved as a result of the chromosomal β-lactamase genes 
escaping from Kluvera spp. Having migrated to mobile DNA, the CTX-M β-lactamases may 
evolve further (Rawat and Nair, 2010).  Unlike most TEM and SHV-derived ESBLs, CTX-M 
beta lactamases hydrolyze cefotaxime and ceftriaxone better than they do ceftazidime. It also 
appears that CTX-M enzymes are more readily inhibited by tazobactam than they are by 
clavulanic acid (Perez, et al., 2007).  According to studies conducted by Rawat andNair 
(2010), it has been suggested that the CTX-M-type ESBLs may now actually be the most 
frequent ESBL type worldwide. 
 
 K. pneumoniae carbapenemase (KPC) is an Ambler class A β-lactamase which confers 
resistance to all β-lactam agents, including carbapenems (Kitchel, Sundin and Patel, 2009). 
The first detection of a blaKPC-positive K. pneumoniae (KPC-Kp) isolate was in 1996 in North 
Carolina. This klebsiella isolate was resistant to all β lactams, but carbapenem minimum 
inhibitory concentrations (MICs) were slightly decrased after addition of one of the β 
lactamase inhibitors, clavulanic acid. The discovery of this plasmid encoded β-lactamase, 
KPC-1, was followed by several publications of another single amino acid variant, KPC-2, in 
hospitalised patients from the east coast of the USA (Nordmann, Cuzon and Naas, 2009). 





however, K. pneumoniae still remains the most common species possessing these enzymes 
(Endimiani et al., 2009). Since its emergence in North Carolina, KPC-Kp has caused serious 
outbreaks in several countries including Israel and China.  
Ambler class B (Bush Group 3) enzymes are metallo-beta-lactamases (MBLs) that use one of 
two zinc (Zn2+) atoms for inactivating penicillins and cephalosporins suggesting that the 
MBLs are likely to have evolved separately from the other Ambler classes, which have serine 
at their active site (Drawz and Bonomo, 2010). MBLs were first formally categorized from 
serine β-lactamases in 1980 in the classification scheme proposed by Ambler. In 1989, Bush 
further classified MBLs into a separate group (group 3) according to their functional 
properties and remains the recommended referencing system for β-lactamases. This scheme 
was primarily based on substrate profiles, their sensitivity to EDTA, and their lack of 
inhibition by serine β-lactamase inhibitors (Walsh et al., 2005). 
 
In bacteria, MBLs confer resistance to carbapenems, cephalosporins and penicillins. The class 
B β-lactamases are completely distinct from the serine β-lactamases in terms of sequence, 
fold and mechanism. There are three subclasses of class B MBLs (B1 to B3). Classes B1 and 
B3 are able to bind one or two zinc ions, whereas the class B2 enzymes appear to be mono-
nuclear (Wilke et al., 2005).  In the bi-nuclear MBLs, the zinc ions are p oximal to each other 
and are separated by a bridging hydroxide that has been proposed to be the attacking 
nucleophile in β-lactam hydrolysis. The class B1 and B3 MBLs can also function as mono-
nuclear enzymes, in which a single zinc ion (that occupies the Zn1 site) coordinates the 
nucleophilic hydroxide; it has been suggested that is mechanism predominates in the 
presence of substrate under physiological conditions (Wilke et al., 2005). The MBLs have 
poor affinity or hydrolytic capability for monobactams and are not inhibited by clavulanic 
acid or tazobactam. Instead, they are inhibited by metal ion chelators such as EDTA (Bush 
and Jacoby, 2010). 
   
Ambler class C enzymes (Bush Group 1) include the cromosomally encoded AmpC type 
beta-lactamses found in Citrobacter freundii, Enterobacter aerogenes and Enterobacter 
cloacae (Babic, Hujer and Bonomo, 2006).  Characteristically, AmpC β-lactamases provides 
resistance to cephamycins as well as to oxyimino-β-lactams and are resistant to inhibition by 
clavulanic acid (Jacoby and Munoz-Price, 2005). The sequence of the ampC gene from E. coli 
was reported in 1981. It differed from the sequence of penicillinase-type β-lactamases such as 
TEM-1 but, like them, had serine at its active site (Jacoby, 2009).  The chromosomally 
encoded β-lactamases have been a subject of intense study since the 1980s. Most of these 





cephalosporins. The chromosomal β-lactam hydrolyzing gene, ampC, of Escherichia coli K-
12 was first to be cloned and sequenced (Kong et al, 2010). Plasmid-mediated AmpC β-
lactamases have been found worldwide but are less common than extended-spectrum β-
lactamases, and in E. coli, they appear to be less often a cause of cefoxitin resistance than an 
increased production of chromosomal AmpC β-lactamase (Jacoby, 2009). AmpC enzymes 
encoded by both chromosomal and plasmid genes are evolving to hydrolyze broad-spectrum 
cephalosporins more efficiently and according to much of the literature there needs to be 
improvements in clinical detection of these enzymes lest the intensity of their resistance 
mechanisms be underestimated (Jacoby, 2009). 
 
OXA,   an abbreviation for oxacillin-hydrolyzing β-lactamases, represented one of the most 
prevalent plasmid-encoded β-lactamase families in the late 1970s and early 1980s (Queenan 
and Bush, 2007). Ambler class D (Bush group 2f), are serine β-lactamases that are able to 
hydrolyze oxacillin. The OXA enzymes of Acinetobacter baumannii and P. aeruginosa 
represent the most structurally diverse and rapidly growing group of beta-lactamases.  
Depending on the OXA enzyme, these beta-lactamases confer resistance to penicillins, 
cephalosporins, extended-spectrum cephalosporins (OXA-type ESBLs) or carbapenems 
(OXA-type carbapenemases). OXA enzymes are relativey r sistant to clavulanic acid 
inactivation, but are inhibited by sodium chloride (Babic, Hujer and Bonomo, 2006).  Some 
confer resistance predominantly to ceftazidime (Jacoby, 2005). 
 
1.5 ESBLs in South Africa and Africa 
 
ESBLs are now a problem worldwide but the phenomenon began in western Europe most 
likely because that is where ESBLs were first used clinically (Bradford, 2001). The 
epidemiology of ESBLs vary among institutions, Meyer et al., (2007), reported SHV and 
TEM type ESBLs in Pretoria Academic Hospital.  Essack, Hall and Livermore, (2004) 
reported the presence of five β-lactamase genes in a single South African K. pneumonia 
isolate. Several outbreaks of infections with ESBL-producing Klebsiella have been reported 
from South Africa previously. In 2006, carbapenem-resistant, ESBL producing K. Pneumonia 
were detected in Cape Town and this has led to resea ch rs in other institutions investigate the 
prevalence of these enzymes (Meyer et al., 2007).   
 
In 2008, Govinden et al., reported TEM-63 in Salmonella spp. which was first reported by 
Essack et al., (2001) in K. pneumonia isolates. The same study included the presence of TEM 
– 131 and TEM-116, the latter, reported for the first time in South Africa in Salmonella spp. 





CMY type β-lactamases in unique combinations which was a rare occurrence as well as the 
discovery of CTX-M-37 being reported for the first time in South Africa (Govinden et al., 
2008). Another study investigating the β-lactamases in E. coli in state hospitals in Kwa-Zulu 
Natal in 2009 also revealed a great deal  of diversity of β-lactamase genes reporting CMY, 
SHV, OXA, CTXM, TEM as well as two novel inhibitor resistant  TEM β- lactamases, TEM-
145 and TEM 146 (Mocktar et al., 2009).  
 
ESBLs have also been documented in Israel, Saudi Arabia, and a variety of North African 
countries. Outbreaks of Klebsiella infections with strains resistant to third-generation 
cephalosporins have been reported in Nigeria and Kenya without definitive identification of 
the ESBL (Paterson, 2005). Okesola and Makanjuola, (2009) reported a notable increase in 
resistance in Klebsiella spp., with69 % of the isolates tested showing resistance to third 
generation cephalosporins. A novel CTX-M enzyme (CTX-M-12) has been found in Kenya. 
Characterization of ESBLs from South Africa has revealed TEM and SHV types (especially 
SHV-2 and SHV-5). (Paterson, 2005) 
 




Transduction occurs when viral particles, known as b cteriophages, pick up chromosomal 
DNA from the donor bacteria and transfer it to recipient cells by infection (Figure 1.7), 
(Lartigue et al., 2007).  Transduction is responsible for some of the transfer of bacterial drug 
resistance genes among clinical strains of Staphylococcus aureus.  Fragments of bacterial 
genomes or small bacterial plasmids can be moved from one bacterial cell to another in this 
way. Survival of the DNA in the new cell requires eith r ‘rescue’ by recombination or the 
transferred DNA must be able to replicate independently in its new host. If the DNA is a 
linear fragment of a larger replicon, such as a fragment of the chromosome of the cell in 
which the phage reproduced, then any genes on it will only survive if they are rescued by 
recombination (Bennett et al., 2004). Homologous recombination is a DNA metabolic process 
that provides high fidelity, template dependent repair or tolerance of complex DNA damages. 
It plays a prominent role in authentically duplicatng the genome by providing critical support 







Fig 1.7 Illustration of the process of transduction where bacteria may become antibiotic 





Transformation refers to the process of bacteria taking up ‘naked’ or ‘free’ DNA (Figure 1.8). 
This DNA is generally recombined into the recipient chromosomes to form genetic 
recombinants (Lartigue t al., 2008).  This mechanism involves only DNA and requires the 
release of DNA from the donor cell, by cell lysis after which the gene must be rescued by the 
recipient cell so to prevent degradation (Bennett et al., 2004). Simply, a whole bacterial 
genome or fragments of the genome from one species is transformed into another bacterial 
species, which results in new cells that have the genotype and the phenotype of the input 
genome (Lartigue et al., 2008). The antibiotic resistance may therefore be a result of the 
bacteria acquiring foreign genetic material and incorporating free DNA segments into their 


























Fig 1.8 Illustration of the process of transformation where bacteria may acquire resistance 




Conjugation (Figure 1.9) is a key mechanism for horizontal gene transfer in bacteria, this 
allows bacteria to acquire genes for antibiotic resistance as well as other attributes (Babic et 
al., 2008).  In the case of transduction and transformation, these two mechanisms depend on 
the recipient to participate in the process via homol gous recombination; conjugation requires 
the participation of either a conjugative plasmid or a conjugative transposon, each of which 
encodes a DNA transfer system that has evolved to specifically mediate this horizontal 
transfer (Bennett et al., 2004,). An important feature of conjugation is that a single donor cell 
can convert a population of recipient cells to donor cells especially in the spread of an 
outbreak (Frost and Koraimann, 2010).  In addition  functions involved in their replication 
and transfer, plasmids have been known to encode resistance to one or many antibiotics. 
Some plasmids can transfer between different species whereas others are confined to one 
genus or species. Therefore a plasmid does not need to r side only in a particular host in order 


























Fig 1.9 Illustration of bacterial conjugation involing the transfer of genetic material vis 
plasmids or conjugative transposons (Alekshun and Levy, 2007). 
 
1.6.4 Mobile genetic elements 
 
These plasmids and transposons are referred to as mobile genetic elements. Mobile genetic 
elements fall into two types: elements that can move from one cell to another such as 
plasmids and conjugative transposons and elements that can move from one genetic 
localization to another in the same cell such as trnsposons, gene cassettes and insertion 
sequences (IS) (Bennett, 2009).  
 
Plasmids have been described as small, auxiliary, dispensable chromosomes. Conjugative 
plasmids are plasmids that are able to promote their own transfer and the transfer of other 
plasmids from one bacterial cell to another   In geeral; they exist separately from and are 
replicated independently of the main bacterial chromosome (Bennett, 2009).   Transposons 





They come in many forms, recognized by structure, genetic relatedness and mechanism of 
transposition and can carry a variety of resistance genes (Bennett et al., 2004).  Transposons 
belong to the set of mobile elements called transposable elements that encompass small 
cryptic elements called insertion sequences (Bennett, 2009).  Insertion sequence elements are 
small and may vary in size between 0.8 and 2.5 kb and they encode very specific functions 
required for their transposition. IS elements may be present in one or several copies and 
contained on plasmids, or chromosomes and they mustreside on the conjugative plasmid for 
intercellular transfer (Depardieu et al., 2007).   
 
Integrons are elements that are capable of insertion, excision and expression of gene cassettes 
(Grape et al., 2005). They comprise a site-specific recombination system that recognizes and 
captures mobile gene cassettes. An integron includes a gene for an integrase (int) and for an 
adjacent recombination site (attI) (Fluit and Schmitz, 2004).  A gene cassette is a mall 
autonomous, non-replicating, double-stranded, circula  DNA molecule found on integrons 
(Bennett, 2009). Integrons can be divided into two gr ups: Resistance Integrons (RIs) and 
Super Integrons (SIs). RIs carry gene cassettes that encode resistance against antibiotics and 
are primarily located on the chromosome or the plasmid. The SI group is large and 
chromosomally-located with gene cassettes which contain a variety of functions (Fluit and 
Schmitz, 2004).  The insertion of a gene cassette is str ctly oriented so that the start of the 
gene carried by the cassette is the nearest int. Gene cassettes can be inserted one after the 
other into the integron insertion site, attI, therefore producing impressive resistance gene 
arrays (Bennett, 2009).  
 
The four classes of integrons so far identified are class 1, 2, 3 and 4. They are distinguished 
by their respective integrase (int) genes. Class 4 is a distinctive class of integrons l cated in 
the Vibrio cholerae genome and is not known to be associated with antibiotic resistance 
(White, McIver and Rawlinson, 2001).  Most RI conforms to a structure known as a class 1 
integron (Figure 1.10). Class 1 integrons have been r ported in many gram negative bacteria 













Fig 1.10 A schematic representation of a class 1 integron with a gene cassette. P1, promoter 
for the transcription of gene cassettes; P2,  second promoter that is usually inactive; int, 
integrase gene; attI1, the integration site; qacE, partially deleted gene that encodes quartenary 
ammonium compound (disinfectants and antiseptics) resistance; sulI, sulphonamide 
resistance; attC, sequence on the gene cassette recognized by the integrase (Fluit and Schmitz, 
2004).  
 
Broad spectrum β-lactam antibiotics were introduced in 1981 and shortly after their release, 
ESBL producing organisms were discovered in Germany in 1983. To date the rise of these 
infections has become significant enough for it to be recognized and in recent years the 
phenomenon of multi drug resistance (MDR) has been raised (Hyle et al., 2005).  MDR can 
be defined as the resistance to multiple antibiotics and or other antibiotic classes in addition to 
the β-lactam antibiotics (Zhao et al., 2010).  As previously mentioned, class 1 integrons make 
up the majority of the integrons found in clinical isolates and they have been associated with 
MDR in hospital settings (Leverstein van Hall, et al., 2003).  Much of the literature has 
associated class 1 integrons with MDR due to the gene cassettes expressing the qacE and the 
sulI genes. MDR has been described particularly in K. pneumonia isolates by Zhao et al., 
(2010). They discovered that more than 27 plasmids in K. pneumonia isolates were found to 
carry genetic determinants for MDR. Another study found metallo β-lactamases embedded in 
gene cassettes on a class 1 integron specifically in a K. pneumonia isolate that showed MDR 








1.7 K. pneumonia  
 
K. pneumonia has been a known human pathogen since the late nineteenth century when it 
was first isolated by Edwin Klebs. It is often called Friedlander's pneumonia, in honor of the 
first man who identified it as a significant respiratory pathogen back in 1882. Although 
Klebsiella is most often thought of as a nosocomial pathogen, it can also be a cause of serious 
infection acquired outside the hospital (Prince et al., 1997). Klebsiella is a Gram-negative, 
non-motile and rod-shaped bacterium, which can livein water, soil and plants and is 
pathogenic to humans and animals (Zhao et al., 2010).  Klebsiellae are protected from drying 
by their capsule and so survive better than other Enterobacteriaceae on skin and fomites, 
facilitating cross-infection (Yuan et al., 1998).  It is a common hospital-acquired pathogen, 
causing urinary tract infections, nosocomial pneumonia and intra-abdominal infections (Ko et 
al., 2002).  A geographic difference in this organism has been recognized and several 
outbreaks of various infections have been documented.  Extensive use of broad spectrum 
antibiotics in hospitalized patients has led to both increased carriage of Klebsiella, and 
subsequently, the development of MDR strains that produce ESBLs (Zhao et al., 2010).   
 
Until the mid-1980s, resistance to broad spectrum β-lactam antibiotics was known to be 
limited to organisms with inducible chromosomal β-lactamase genes; this form of resistance is 
not transmissible (Jain et al., 2003). It was a surprise when a species of Klebsiella with 
plasmid-mediated resistance to extended-spectrum cephalosporins was isolated in Germany in 
1983, and in the following year, similar resistance in Klebsiella was reported in France (Jain 
et al., 2003). Being encoded on plasmids enables these enzym s to be easily transmissible 
from one organism to another. K pneumoniae is by far the most common species in which 
ESBL has been recognized, accounting for 75% of ESBL-producing isolates. Plasmid-
mediated ESBL production had been detected in 14–16% of K. pneumoniae isolates in 
Europe in 2001 (Menashe et al., 2001).  
 
It is important to note though that cross-infection is ot the only explanation for dissemination 
of ESBLs, plasmid transfer is also an important consideration.  In the first major outbreak of 
ESBL producers, Sirot, (1995), documented transmission of plasmids encoding TEM-3 β-
lactamase between different Klebsiellae and to other Enterobacteriaceae (Yuan et al., 1998). 
Several studies have shown that ESBL-producing Klebsiella strains have an increased ability 
to adhere to human epithelial cells, probably due to plasmid-coded production of fimbrial or 
nonfimbrial adhesins (Sahly et al., 2004).  Resistance appeared initially in organisms uch as 
Enterobacter cloacae that could, by mutation overproduce their chromosomal AmpC.  Later, 





as K. pneumonia and this resistance was found to be mediated by plasmids encoding ESBLs 
(Philippon, Arlet and Jacoby, 2002).  Plasmid-mediated AmpC beta-lactamases have arisen 
through the transfer of chromosomal genes for the inducible AmpC beta-lactamase onto 
plasmids. This transfer has resulted in plasmid-mediat  AmpC beta-lactamases in isolates of 
Escherichia coli, K. pneumoniae, Salmonella spp., Citrobacter freundii, Enterobacter 
aerogenes, and Proteus mirabilis Plasmid-mediated AmpCs differ from chromosomal AmpCs 
in that they are uninducible (Thomson, 2001).  
 
Like their counterpart on the chromosome, such enzymes provided a broader spectrum of 
resistance of ESBLs and were not blocked by commercially available inhibitors.  
Furthermore, in a strain with decreased outer membrane permeability such enzymes can 
provide resistance to carbapenems as well, as has been observed with clinical isolates of K. 
pneumoniae during an outbreak in New York (Philippon, Arlet and Jacoby, 2002). 
 
It is anticipated that Klebsiella strains will become more virulent and resistant to antibiotics in 
the future, an eventuality that could contribute to the spread of certain Klebsiella clones by 
virtue of their greater resistance to antibiotics and better adherence to host tissues (Sahly et 
al., 2004). 
 
1.8 Resistance containment Strategies 
 
Various strategies have been proposed to improve use of antibiotics and prevent the 
emergence of antibiotic resistance.  Antibiotic practice guidelines or protocols have emerged 
as a potentially effective means of both avoiding unnecessary antibiotic administration and 
increasing the effectiveness of prescribed antibiotics. Restricting specific antibiotics or 
antibiotic classes from the hospital formulary has been adopted as a strategy to reduce the 
occurrence of antibiotic resistance and antimicrobial costs. Such an approach has been shown 
to reduce pharmacy expenses and adverse drug reactions from the restricted drugs (Okesola 
and Makanjuola, 2009).  Another proposed strategy to curtail the development of 
antimicrobial resistance, in addition to the judicious overall use of antibiotics, is to use drugs 
with a narrow antimicrobial spectrum or "older" antibiotics. Several investigations suggest 
that some infections, uch as community-acquired pneumonia and urinary trct infections, can 
usually be successfully treated with narrow-spectrum antibiotic agents, especially if the 






It is evident that K. pneumonia has a significant predilection to resistance mechanisms of 





To elucidate the molecular epidemiology of β-lactamase mediated resistance, in selected K. 
pneumonia isolates from a tertiary hospital in KwaZulu-Natal, South Africa and to ascertain 




1. To determine the production of ESBLs by using the double disk synergy test (DDST) 
for ESBL detection. 
2. To undertake preliminary typing of β-lactamases on the basis of MICs. 
3. To undertake DNA sequencing to definitively identify the ESBL genes and to 
correlate genotypes with phenotypes.  
4. To investigate genetic determinants of resistance via plasmid banding patterns 



























2.1 Bacterial Isolates 
 
The 24 putative ESBL positive K pneumonia isolates investigated in this study were collected 
from a tertiary hospital in KwaZulu-Natal, South Africa. Of the 13 K. pneumonia isolates 
collected in the year 2000, 5 were tested as ESBL positive. These were KEH 3, 6, 21, 81,100.  
These isolates formed part of a previous study by Essack et al., which was undertaken to 
evaluate the appropriateness of nationally devised tandard treatment guidelines (STGs) 
within the public healthcare system in KwaZulu-Natal.  The study highlighted the importance 
of surveillance-based treatment guidelines for infections over the guidelines set by expert 
committees as the former takes into considerations many factors such as, microbial etiology 
of the disease, antibiotic use and antibiotic resistance (Essack et al., 2005).  
 
The remaining isolates were collected in 2007 and formed part of an active, disease-based 
surveillance study also ascertaining the appropriateness of treatment guidelines, but on a 
disease basis. The isolates were collected from three ospitals, one district, one regional and 
one tertiary. K. pneumoniae featured as a causative organism in nosocomial infect ons and K. 
pneumoniae isolated in the tertiary hospital were included in this study.  
 
Of these, 14 were subjected to full laboratory investigations as a result of cost constraints. 
 
2.1.1 Ethical Considerations 
 
This study as well as the study by Essack et al., (2005) had ethical clearance from the 
University of KwaZulu-Natal. 
 
2.2 Bacterial Identification 
 
The isolates were identified using the API 20E system (bioMerieux, Lyons, France) as per the 










2.3 Susceptibility Testing 
 
2.3.1 Agar Dilution 
 
The microbiological parameter used since the beginning of antibiotic therapy is the minimum 
inhibitory concentration (MIC). The MIC is defined as the lowest concentration of a drug that 
will inhibit the visible growth of an organism after overnight incubation (Andrews, 2001).  
MICs are used to confirm unusual resistance, to give definitive answers when borderline 
results are obtained or when disk diffusion methods give false negative results (Dalhoff, 
Ambrose and Mouton, 2009). 
 
Agar dilution and broth dilution are the most commonly used methods to determine MICs 
where bacterial cell suspensions are dotted directly onto the agar plates that have integrated 
different antibiotic concentrations. Broth dilution uses a liquid growth medium containing 
geometrically increasing concentrations of the antibiotic which is inoculated with a defined 
number of cells (Wiegand, Hilpert and Hancock, 2008).  
 
The advantage of both the broth and agar dilution methods is that both techniques generate 
very good quantitative results. The disadvantage of using the broth dilution method is that the 
manual task of preparing the antibiotic solutions is tedious and the possibility of errors in the 
Table 2.1 A list of the Bacterial Test Isolates used in the study and the year of collection 
Bacterial Isolate Year of Isolation Bacterial Isolate Year of Isolation 
KEH100 2000 KEH3328 2007 
KEH3 2000 KEH3409 2007 
KEH21 2000 KEH2786 2007 
KEH6 2000 KEH3434 2007 
KEH81 2000 KEH3281 2007 
KEH1506 2007 KEH2605 2007 
KEH2093 2007 KEH2787 2007 
KEH1883 2007 KEH2924 2007 
KEH7123 2007 KEH893 2007 
KEH3217 2007 KEH2007 2007 
KEH7689 2007 KEH6740 2007 





preparation is very high. The biggest concern however is the interpretation of results. Micro 
broth dilution has been widely used which uses an automated system to interpret results 
however, this technique requires a large amount of reagents and is not a very cost effective 
method (Jorgensen and Ferraro, 2009). 
 
The agar dilution technique has shown accuracy in determination of MICs specifically when a 
full dilution range of the antibiotic is used. This technique also enables the testing of many 
organisms against a succession of dilutions of just a ingle antibiotic concurrently as well as 
the possibility of extending the concentrations of antibiotics as far as is required (Varela t al., 
2008). MICs are a good phenotypic indicator to determine the resistance or susceptibility of 
an isolate to antibiotics; however, it is inconclusive with respect to the mechanism of 
resistance to the antimicrobial agent. (Wiegand et al.,  2008). Phenotypic measures of the 
level of susceptibility of bacterial isolates to antimicrobial agents are nevertheless largely 
relevant due to mutations, gene acquisitions, and expression mechanisms in multi-drug 




• Test Isolates 
• Control Isolate E. coli 25922 
• Antibiotic stock solutions (Sigma-Aldrich®) 
• Mueller Hinton Agar (Biochemika, Fluka Sigma-Aldrich®) 
• Mueller Hinton broth (Biochemika, Fluka Sigma-Aldrich®) 
• Sterile distilled Water 
• 0.5 M McFarland standard 
 
Apparatus: 
• Automated 48-pin replicator for inoculation (Boekel Scientific). This apparatus 
enables the pins to dip into the micro-titre plate containing the inoculum and then dot 
the inoculum onto the surface of the agar. It is effici nt and prevents cross 
contamination. 










 The antibiotic stock solutions were prepared using the solvents and diluents for 
preparation of stock solutions of antimicrobial agents as per the guidelines contained 





)( ×=  
 
 Where P = the potency given by the manufacturer (µg/mg) 
 V = the volume of antibiotic is required.  The desir d volume was 20ml 
 C = the final concentration required. The desired concentration was 10 mg/L 
W = the weight of the antibiotic required to be dissolved in V. (Wiegand et al., 2008)  
 
 The antibiotic dilution range depending on the CLSI break points for resistance and 




















 The Mueller Hinton agar plates were prepared in sterile 30 ml labeled bottles and 
autoclaved. The agar was cooled down to 50 °C and then the antibiotic dilutions were 
added into respective bottles and plated accordingly.  
Table 2.2 Antibiotic dilution chart for agar dilution method. 
Antimicrobial Volume of antibiotic Final concentration 
concentration stock solution when adding 
(mg/L) (ml) 25 ml agar 
10 640 256 
10 320 128 
10 160 64 
10 40 16 
1 200 8 
1 100 4 
1 50 2 
0.1 250 1 
0.1 125 0.5 
0.1 62.5 0.25 





 The inoculum was prepared using Mueller Hinton broth. Individual colonies were 
transferred into the broth and incubated at 37°C for 4-6 hours until the turbidity 
resembled the 0.5 M McFarland standard. The isolates w re adjusted to match the 
McFarland with sterile distilled water if necessary nd the inoculum was used within 
30 minutes 
 The inoculum was pipetted using a micro pipette into the sterilized 96 well micro-titre 
plate along with the positive and negative controls. 
 The agar plates were aligned on the base and the auom ted pin replicator transferred 
small volumes of inoculum from the micro-titre plate onto the Mueller Hinton Agar 
plates.   
 The plates were incubated overnight at 37°C. 
 The MIC was determined as the lowest concentration that showed no growth after 
overnight incubation. 
 
2.3.2 Tests for the detection of ESBLs  
 
 Agar dilution and disk diffusion screening methods have been recommended by the CLSI. 
There are criteria and interpretive standards to assist in the phenotypic screening for ESBL 
positive isolates. Based on the MIC breakpoints provided by the CLSI to ascertain the 
expression of ESBLs, disk diffusion tests are used for confirmation, however, many studies 
use both agar dilution and disk diffusion for confirmation of ESBL production as disk 
diffusion alone has shown false positives with errors in the detection of ESBL-mediated 
resistance encountered with both automated and manual disk diffusion methods (Perez t al., 
2007).  Using disk diffusion methods for antibiotic susceptibility testing can screen for ESBL 
production by noting specific zone diameters which indicate a high probability of ESBL 
production (Paterson and Bonomo, 2005).If the zone diameters indicate a suspicion for ESBL 
production then further phenotypic tests must be carried out for confirmation of ESBLs.  
Inaccurate identification of ESBL producers has clini al implications as well as for antibiotic 
use and it is therefore imperative that detection guidelines are adhered to. 
 
Since the 1980’s specific phenotypic tests have been d veloped for ESBL detection, whether 
it be disk diffusion on agar, MIC determination or automated systems (Drieux, et al., 2008). 
There has been extensive research into these screening methods with specific attention to their 
accuracy and rapidity.  The double disk synergy test, the three dimensional test, the E Test 
and the Vitek test, including their modifications have been introduced as screening methods 






The ESBL E test has been developed to measure the interaction between extended spectrum 
cephalosporins and clavulanate. The E tests are plastic, two sided strips containing gradients 
of cefotaxime, ceftazidime or cefepime either alone  one side of the strip or combined with 
clavulanate on the other end (Drieux, et al., 2008). A positive test result is the reduction of the
test drugs MIC by a ratio of ≥8 in the presence of clavulanate. A positive result can also be 
confirmed by the presence of a rounded or a phantom zone below the lowest concentration of 
the test drug and a deformation of the inhibition ellipse at the tapered end of the test drug 
(Drieux, et al., 2008). The E- test may fail if the MIC values for the cephalosporins fall 
outside the range of those present on the test strip (Linscott and Brown, 2005) and the reading 
of the inhibition zones may very well influence result  negatively as these zones have been 
frequently reported as complex due to the presence of mutants along the zone border. It is 
therefore imperative that researchers and technicians be well trained to recognize the subtle 
ellipse deformations and phantom zones (Leverstein-van Hall, et al., 2003).  
 
The VITEK 2 test,  a relatively new modification and is an improvement on the VITEK 1 
because of its increased specificity, is an automated ESBL test which uses the antimicrobial 
susceptibility data generated to suggest the phenotype of the tested isolate and thereby 
determine the susceptibility and resistance to antibiotics not tested (Schwaber, et al., 2005) 
This test assesses the antibacterial activity of cefepime, cefotaxime and ceftazidime either 
alone or in the presence of clavulanate while making use of card wells containing the test 
drugs in various concentrations either alone or in combination with clavulanate. After 
inoculation the cards are introduced into the VITEK 2 machine where the turbidity is 
measured for each antibiotic tested and the proporti nal reduction of growth in the wells 
containing cephalosporin with clavulanate is compared to the cephalosporin alone and is then 
interpreted ESBL positive or negative (Drieux, et al., 2008). The VITEK test is not as cost 
effective as manual methods and has rendered false po itives. This test has shown a low 
specificity with numerous false positives reported in many studies (Wiegand et al., 2008) and 
it has been reported that the VITEK test should not be used as the sole method of detection 
until further studies prove otherwise (Schwaber et al., 2006). 
 
The three dimensional test proposed by Thomson et al., (1984), is a modification of disk 
diffusion tests and it demonstrates substrate specificities of bacterial β-lactamases present. 
The test involves inoculating the surface of the agar with a 0.5 McFarland of the test organism 
and a higher density of inoculum is dispensed into a circular slit in the agar just 3mm from the 
antibiotic disks. The test as described by Thomson et al., (1984), inoculates a control strain on 
the inner surface before the slit and the test organism inoculated on the outer surface after the 





through the slit, results in a distortion or a discontinuity in the circular inhibition zone 
(Drieux, et al., 2008).  Since its discovery there have been many modifications to the three 
dimensional test, specifically to test the presence of AmpC β-lactamases. It has been reported 
that the technique proved to be difficult in terms of the circular slit and some modifications 
involved linear slits but having to fill the slits with the enzyme extracts proved to be tedious 
(Manchanda and Singh, 2003).  The technique does have its advantages as it requires less 
training and minimal reagents and has not had very high reports of false positives with high 
detection rates (Drieux, et al., 2008; Manchanda and Singh, 2003). 
 
2.3.3 Double Disk Synergy Test (DDST) 
 
The DDST is a very cost-effective technique has been used in a wide range of 
Enterobactericeae, it is regarded as a reliable test but sometimes it is necessary to adjust the 
spacing between the disks to increase its reliability (Drieux, et al., 2008). The technique is 
relatively simple however the interpretation of the results is subjective. There have been 
instances where false-negative results have been reported with isolates harboring the SHV-2, 
SHV-3 or TEM-12 ESBLs. In addition to that, sensitivity may be reduced when ESBL 
expression is very low, leading to wide zones of inhibition (Rawat and Nair, 2010). 
According to CLSI guidelines, isolates which have a positive phenotypic confirmatory test 
should be reported as resistant to all cephalosporins (except the cephamycins,) and aztreonam. 
β-lactam/β-lactamase inhibitor combinations such as ticarcillin-c avulanate or piperacillin-
tazobactam must be reported as susceptible if MICs or zone diameters are within the 
appropriate range (Rawat and Nair, 2010). 
 
2.3.4 Tests for the detection of AmpC β-lactamases 
 
The detection of AmpC’s has proven to be a challenge for many laboratories. There has been 
methods devised based on disk diffusion methodology by many laboratories to detect 
AmpC’s. Nasim et al., (2004), studied the use of a cefoxitin agar medium (CAM) in 
comparison to a modified three dimensional AmpC assay (M3D). The CAM assay which is 
time consuming and labor intensive gave the authors a similar result to the M3D, however 
like many studies gave false positives. A study by Coudron, Hanson and Climo (2003), 
reported on the inconsistency in their phenotypic testing of AmpC’s as the disk diffusion 
showed 15% AmpC positives but that number was further reduced by the three dimensional 
test and isoelectric focusing. The detection of plasmid mediated AmpC’s prove to be very 
technically demanding with the use of methods that were time consuming and although a few 





to perform an AmpC disk test based according to Black, Moland and Thomson (2005), which 
is based on the use of TRIS-EDTA which permeabilizes th  bacterial cell wall and releases β-
lactamases into the external environment. The test allows for six isolates to be tested at a time 
and the interpretation was straightforward.  The authors reported a very high number of 
positive isolates in their study (95%) indicating the accuracy, simplicity and convenience of 
using such an assay. They did report however that teir study did not include plasmid 
mediated AmpC’s however additional studies showed positive results in other 
enterobacteriaceae. Genetic testing will however be necessary as a follow up on such isolates. 
 
In this study both the agar dilution as well as the double disk synergy test was used to confirm 
ESBL producers. The TRIS-EDTA disk test was used to confirm AmpC producers. The disk 




• Test Isolates 
• E coli positive Control 25922  
• ESBL - producing isolate from a previous study (Essack, Connolly and Sturm, 2005)) 
• Mueller Hinton Agar (Biochemika, Fluka Sigma-Aldrich®) 
• Mueller Hinton Broth(Biochemika, Fluka Sigma-Aldrich®) 
• Antibiotic Disks (Oxoid) 
 Amoxicillin-clavulanate (AMC) 
 Ceftazidime (CAZ) 
 Cefuroxime (CROX) 
 Cefotaxime (CTX) 
 Aztreonam (AZT) 
• 0.5 M McFarland Standard  
 
Procedure: 
 A few colonies were picked from overnight growth on Nutrient Agar and inoculated 
into 5 ml of Mueller Hinton Broth 
 The broths were incubated at 37°C overnight until turbid 
 The turbidity was matched to the 0.5 M McFarland standard (Appendix 1) with sterile 
distilled water 
 A sterile cotton swab was dipped into the broth andpressed firmly above the fluid 





 The swab was then streaked over the entire agar surface several times until the 
inoculum was evenly distributed 
 The plates were left to dry for 2-5 minutes but not m re than 10 minutes 
 The following disks were placed onto the agar: Aztreonam (AZT), Ceftazidime 
(CAZ), Cefuroxime (CROX), Cefotaxime (CTX) and Amoxicillin/Clavulanate 
(AMC). The AMC disks were placed at the centre and the rest were placed around the 
centre not less than 25 mm apart from each other as well as from the AMC disk. 
 Plates were incubated at 37°C overnight. 
 An enhancement of the zone nearest to the AMC disk indicated a positive test for 
ESBLs. 
 
The TRIS-EDTA test was performed with modifications as follows: 
 
Materials 
• Test Isolates 
• E coli  positive Control 25922 
• Putative AmpC producers from a previous study (Essack, Connolly and Sturm, 2005)  
• 10X TRIS-EDTA (appendix one) 
• Mueller Hinton Agar (Biochemika, Fluka Sigma-Aldrich®) 
• Mueller Hinton Broth(Biochemika, Fluka Sigma-Aldrich®) 
• Cefoxitin Antibiotic Disks (Oxoid) 
• Sterile filter paper disks 
• Saline 
• 0.5 McFarland Standard  
 
Procedure: 
 A few colonies were picked from overnight growth on Nutrient Agar and inoculated 
into 5 ml of Mueller Hinton Broth 
 The broths were incubated at 37°C overnight until turbid 
 The turbidity was matched to the 0.5 M McFarland standard (Appendix 1) with sterile 
distilled water 
 Sterile filter paper disks (AmpC disks) were prepared by applying a 1:1mixture of 
saline and 10X TRIS-EDTA and were then stored at 8 °C 
 A sterile cotton swab was dipped into the broth containing the E. Coli 25922 and 





 The swab was then streaked over the entire agar surface several times until the 
inoculum was evenly distributed 
 Three cefoxitin disks were placed 25mm apart on the inoculated surface of the agar. 
 The prepared AmpC disks were inoculated with 20µl of each test isolate prior to use 
and placed on either side of the cefoxitin disk making sure the AmpC disks touch the 
cefoxitin disks. 
 A total of 6 isolates were tested each time 
 
2.4 Plasmid Isolation 
 
Many β-lactamase genes have been found on plasmids in K. pneumonia including those 
encoding ESBLs (Wei et al., 2005).  Plasmid profiling is important to ascertain the diverse 
genetic determinants on which resistance genes reside.  Studies have shown that members of a 
single epidemic strain may carry different plasmids and genotypically non-related strains can 
produce the same ESBL due to plasmid transfer between species.  Independent evolution due 
to antibiotic pressure plays a role as well as it has been found that different plasmids have the 
ability to mediate the same ESBL (Paterson and Bonom , 2005). 
 
In most bacteria, plasmids are the major vector of horizontal gene transfer.  Plasmids are 
capable of self transfer between strains and species which is responsible for the capture of 
different resistance genes which gives rise to the multi drug resistant (MDR) phenotype 
(Hawkey and Jones, 2009). A study by Karisik, et al., (2006) reported multi drug resistant 
strains of E. coli with plasmids exhibiting genetic linkage of three β-lactamase genes, blaCTXM-
15, blaOXA-1 and blaTEM-1.  Plasmids carrying the platform for MDR may spread across different 
bacterial species therefore strategies need to be dev loped to control dissemination of 
antimicrobial drug resistance (Hopkins, et al., 2005; Coque, et al., 2002).  
 
Plasmid isolation and gel electrophoresis was performed according to Kado and Liu 1981.  
 
Materials: 
• Test isolates  
• Positive control E coli 50192 
• SDS buffer (Appendix 1) 
• Tris solution (Appendix 1) 
• 3%SDS/50mM Tris (Appendix 1) 





• 95% Ethanol 
• Agarose (TopVisionTM Fermentas) 
• TE Buffer (Appendix 1) 
• TAE Buffer (Appendix 1) 
• Bromophenol blue  
• Ethidium Bromide (Sigma-Aldrich®) 
• Electrophoresis apparatus 
• UV Gel spectrophotometer (Gel Doc XR, BioRad) 
• 1kb Molecular weight marker (MWM) (Gene ruler TM Fermentas) 
 
Isolation: 
 Cultures were grown on nutrient agar plates overnight and inoculated into 20 ml of 
nutrient broth and incubated overnight at 37 °C.  
 2 ml of broth was pippetted into a labelled eppendorf tube and centrifuged at high 
speed for 5 minutes to pellet the inoculums.  The supernatant was discarded. 
 The pellet was re-suspended in 1 ml of  3%SDS/50mM Tris and incubated at 65 °C 
for 1 hour 
 1 ml of phenol/chloroform was added and allowed to stand at room temperature for 
15 minutes 
 The tubes were centrifuged at high speed for two minutes and removed carefully to 
not disturb the contents of the tube 
 The smallest micropipette was used to extract the upper aqueous phase without 
touching the intermediate phase. This was transferred this into a clean labelled tube. 
 It was centrifuged at a high speed for 5 minutes and the supernatant was discarded. 
 The pellet was washed in ice cold 95% ethanol and ce trifuge again for 3 minutes 
 the supernatant discarded very carefully making sure not to lose the pellet and dried 
in a sterile laminar flow bench. 




 A 0.8% gel using the agarose and TE buffer was prepared. The solution was heated 
over a Bunsen burner stirring constantly. 
 After cooling ethidium bromide was added to the cooled agarose solution at a final 





 The solution was then poured into the gel casting mould and allowed to harden for 50 
to 60 minutes. 
 Once the gel had hardened, the comb was removed ensuring there was no rupture of 
the gel at the bottom of the wells 
 The gel still in the gel plate was put into the electrophoresis chamber and the chamber 
was filled to the marked line with TAE buffer. 
 5 µl of the plasmid DNA isolates were mixed with 2µl of Bromphenol Blue on a 
sheet of parafilm and the 7µl was loaded into the wells starting with the MWM and 
ending with the E. coli 50192 positive control. 
 The lid and power leads were placed onto the apparatus nd electrophoresis was 
carried out at 12V/cm for 1.5 to 2 hours. 
 After adequate migration the gel was placed into the gel doc system to view the 
bands.  
 The gel doc program incorporated the MWM sizes and estimated the size of the 
plasmid bands which were also compared with the positive control. 
 
2.5 PCR and Sequencing to detect β-lactamase genes 
 
PCR and sequencing are the most accurate methods used to definitively identify and 
characterise ESBL genes and these methods are able to work with a large number of isolates 
simultaneously as well as having the ability to detect mutants (Pitout and Laupland, 2008).  
The limiting factor about PCR is that it is not cost-effective and it is also confounded when 
isolates contain multiple genes from the same ESBL family. Genetic determination of 
resistance has the potential to provide a more reliabl  assessment of antimicrobial resistance. 
Genetic methods assess the genotype of an organism whereas conventional susceptibility 
methods assess the phenotype which in some cases is in ufficient due to gene expression 
(Cockerill, 1999).  
 
Genetic methods have been very successful in detecting the presence of blaKPC enzymes as the 
detection of carbapenem-resistant organisms by automated or semi-automated methods have 
been problematic because of the low levels of resistance (Hindiyeh, et al., 2008). PCR and 
sequencing was done on a select number of isolates. Funding was limited hence we were 
unable to sequence every isolate. The objective was to sequence those genes commonly found 
in K. pneumonia on the basis of the MIC results obtained. Subsequent to PCR, isolates were 








• DNA from test isolates 
• Positive control isolates:  E.coli J53 Expressing SHV-1, E.coli J53 Expressing TEM-
1 and E.coli J53 Expressing TEM-2 
• Putative AmpC producers from a previous study (Essack, Connolly and Sturm, 2005). 
• PCR primers (Table 2.3) 
• 2 x PCR Master mix (Inqaba Biotech) 
• Thermocycler (GeneAmp® 9700, ABI) 
• Absolute Ethanol 
• TE buffer 
• Biowave Life Science DNA spectrophotometer (Biochrom) 
 
PCR and sequencing to detect blaSHV and blaTEM genes was undertaken as previously 
described by Essack et al, (2001). PCR and sequencing to detect blaCTX-M, blaCMY, blaOXA and 
blaDHA  genes was undertaken as previously described by Govinden et al, (2008); Kaye, 
(2004); Perez-Perez and Hanson, (2002) and Zhao et l, (2001).  PCR and sequencing to 
detect blaKPC genes was done as previously described by Yigit et al, (2001).   A list of all the 


























 The DNA from test isolates was prepared by growing bacteria overnight on Mueller 
Hinton Agar. Individual colonies were suspended in istilled water. The suspensions 
were heated at 95°C for 3 minutes and the supernatant was used for the PCR 
 1 µl of each primer pair was mixed with 28µl of thepr -mixed master mix and topped 
up to 99µl with sterile distilled water. The last addition was 1µl of the template. 
Table 2.3 PCR primers used for the detection of ESBL genes. 
Enzyme Primers       Reference   
TEM 5’ ATG AGT ATT CAA CAT TTC CG 3’ Essack et al, (2001). 
5’ CCA ATG CTT AAT CAG TGA GG 3’  Essack et al, (2001). 
  
SHV 5’ ATG CGT TAT ATT CGC CTG TG 3’  Essack et al, (2001). 
5’ GTT AGC GTT GCC AGT GCT CG 3’  Essack et al, (2001). 
  
CTX-M-3A 5’ GGTTAAAAAATCACTGCG 3’  Govinden et al, (2008) 
CTX-M-1B 5’ CCGTTTCCGCTATTACAA 3’  Govinden et al, (2008) 
  
CTX-M (F) 5’ TTTGCGATGTGCAGTACCAGTAA 3’  Govinden et al, (2008) 
CTX-M (R) 5’ CGATATCGTTGGTGGTGCCATA 3’  Govinden et al, (2008) 
 
DHA-1  5’ GGGGAGATAACGTCTGACCA 3’ Zhao et al, (2001) 
 5’ TAGCCAGATCCAGCAATGTG 3’ Zhao et al, (2001) 
   
CMY-1           5’ TCACATCGGCTTCACAGAGC 3’ Kaye, (2004) 
 5’ CCATGGTGATGCTGTCAAAGA 3’ Kaye, (2004) 
CMY-2          5’CAACACGGTGCAAATCAAAC 3’ Kaye, (2004) 
 5’CATGGGATTTTCCTTGCTGT 3’ Kaye, (2004) 
   
OXA-1F  5’ ACACAATACATATCAACTTCGC 3’  Perez-Perez and Hanson, (2002) 
OXA-1R     5’AGTGTGTTTAGAATGGTGATC 3’ Perez-Perez and Hanson, (2002) 
   
KPC -1F 5’ CTGGAGGACTATGCACTT 3’ Yigit et al, (2001) 





 PCR was run on the GeneAmp® 9700 and the conditions  f r blaTEM and blaSHVwere 
set at the following: 
95°C for 3 minutes 
30 cycles of 95°C for 1 minute 
   55°C for 1 minute 
   72°C for 1 minute 
 
 The DNA from test isolates from blaCTX-M , blaOXA, blaCMY, blaDHA and blaKPC was 
prepared by growing bacteria overnight on Mueller Hinton Agar. Individual colonies 
were suspended in distilled water they were heat-shocked for 10 minutes at 100°C 
and briefly centrifuged and the supernatant was extracted using a QIAamp DNA Mini 
Kit (Qiagen) 
 
 Conditions for blaCTX-M was set at the following: 
94°C for 3 minutes 
25 cycles 94°C for 30 seconds 
54°C for 1 minute 
72°C for 2 minutes 
72°C for 7 minutes 
 Conditions for blaOXA was set at the following: 
 95°C for 5 minutes 
 30cycles  94°C for 30 seconds 
    62°C for 30 seconds 
    72°C for 30 seconds 
    72°C for 10 minutes 
 Conditions for blaCMY was set at the following: 
94°C for 10 minutes 
 30 cycles 94°C for 1 minute 
   54°C for 1 minute 
   72°C for 2 minutes 
   72°C for 10 minutes 
 Conditions for blaDHA was set at the following: 
94°C for 3 minutes 
 25 cycles 94°C for 30 seconds 
   64°C for 30 seconds 
   72°C for 1 minute 





 Conditions for blaKPC was set at the following: 
30 cycles of amplification 
   94°C for 1 minute 
   55°C for 1 minute 
   72°C for 1 minute 
 
 The PCR product was then purified for sequencing 
 Purification was as follows: 
 
90 µl of PCR product  
10µl of sodium acetate solution 
250 µl of absolute ethanol 
 
 All of the above were added into individual sterile Eppendorf tubes and the tubes 
were incubated at -20°C for 30 minutes.  
 They were centrifuged for 5 minutes at a high speed an  the supernatant was 
discarded 
 They were washed further with 70 % Ethanol and centrifuged at high speed for 5 
minutes 
 The supernatant was discarded and the tubes were left to dry. 
 The pellet was dissolved in 90 µl of TE buffer and was analyzed on the Biowave Life 
Science DNA spectrophotometer to check purity and concentration 
 The remaining 10µl of PCR product was run on an agarose gel to ensure each 
reaction was successful. 
 The purified PCR products were then outsourced to Inqaba Biotech for sequencing. 
 Sequences were analyzed using BLAST 2.0 (Basic Local Alignment Search Tool) 















2.6 Antibiotic Use Data 
 
The daily defined dose (DDD) is the most common method to quantify antibiotic use in 
hospitals (Liem et al., 2010).  The DDD, recommended by the World Health Organisation 
(WHO) is a technical unit of measurement and is based on an assumed average maintenance 
dose per day, for the main indication of the drug, in adults (Filius et al., 2005). Antibiotic use 
data has in many studies proven to be vital in ident fyi g the reason for the decrease in 
susceptibility for many strains of bacteria. It has been widely documented that cautionary use 
of antibiotics may assist in reducing the resistance that has escalated over a number of years.  
Based on previous studies reporting an decrease in usceptibility correlating positively in the 
increase of antibiotic use we wanted to compare the resistance profiles we had with the 
antibiotic use data. 
 
Antibiotic use data was calculated according to Essack et al., (2005). The data was analysed 
for both time frames and were obtained from the hospital pharmacy records. It was expressed 
as usage density rate. The total number of grams of each antibiotic used was divided by the 
number of grams per daily dose for the specific antibiotic, then divided by the patient-days, 
and multiplied by 1 000 to give the number of DDDs per 1 000 patient-days on the 
assumption that all beds within the hospital were 100% occupied at any given time. King 
Edward Hospital (KEH) converted from a tertiary hospital to a district/regional hospital in 
2007, therefore the number of beds in KEH decreased.  
 
2.7 Statistical Analysis 
 
The frequency distribution for utilization and susceptibility was not normally distributed.  The 
data was summarized using median values and interquartile ranges.   Antibiotic use and 
susceptibility in 2000 was compared to that in 2007 using a Wilcoxon signed rank test for 
paired data since the same drugs were tested in both years. The drugs tested in both years are 
as follows: ampicillin, piperacillin sodium, piperacillin/tazobactam, amoxicillin-clavulanate, 
cefuroxime sodium, cefotaxime, ceftazidime, amikacin, gentamicin, nalidixic acid, 
ceftriaxone and ciprofloxacin. The drugs were divided into two groups those that showed a 
decrease in susceptibility and those that did not.  The change in utilization between the years 
2000 and 2007 was then calculated for each group in order to determine if changes in 










RESULTS AND DISCUSSION 
 
The aims of this study was to ascertain the differences if any in the phenotypic and genotypic 
resistance profiles of K. pneumoniae isolated from a single tertiary hospital in two 
surveillance studies undertaken at different times, viz.  2001 and 2007 with special emphasis 
on ESBLs.  A correlation with antibiotic use was alo undertaken. 
 
3.1 Detection and characterisation of ESBLs 
 
The ESBL –producing isolates were confirmed using the double disk synergy test and the 
agar dilution test according to the parameters set by CLSI guidelines to rule out any false 
positive isolates, the data can be seen in tables 3.1 and 3.2.  Figure 3.1 shows a positive result 
for ESBLs by the extension of the ceftazidime (CAZ) zone of inhibition towards the 













Figure 3.1 Isolate KEH 81 showing a positive result for an ESBL using the Doubledisk 
synergy test.  The extension of the zone of inhibition of ceftazidime toward 
amoxicillin/clavulanate confirms the positive result. A – AMC (9mm), B – CAZ (12mm), C – 
CROX (12mm), D – AZT (14mm), E – CTX (12mm). AMC – amoxicillin clavulanate, CAZ 













Table 3.1 MICs (µg/ml), plasmid profiles (Kb) and the genes found in the Isolates collected in 2000. 
2000 AMC CARB P/T CTHIN CRO CTX CAZ CROX AMP IMI AZT 
Plasmid 
Profiles (Kb) Gene/s 




KEH3 8 256 4 256 128 32 4 16 128 0.125 16 207; 59.6; 27 
TEM 1, 
SHV 2 
KEH100 8 256 8 256 16 8 8 16 128 0.125 4 207; 56; 5 
TEM1, 
SHV1 
KEH21 32 256 16 256 0.25 4 4 8 128 0.125 1 
207; 154; 59.6; 
24; 10; 3; 1.3 
TEM 1, 
SHV 2 
KEH81 16 256 16 256 16 64 8 16 128 0.125 4 207 
TEM 1, 
SHV1 
AMC – Amoxicillin/Clavulanate, Carb – Carbenicillin, P/T – Piperacillin/Tazobactam, CTHIN – Cephalothin,  CRO – Ceftriaxone, CTX – 











AMC – Amoxicillin/Clavulanate, Carb – Carbenicillin, P/T – Piperacillin/Tazobactam, CTHIN – Cephalothin,  CRO – Ceftriaxone, CTX – 
Cefotaxime, CAZ – Ceftazidime, CROX – Cefuroxime, AMP – Ampicillin, IMI – Imipenem, AZT – Aztreonam 
Table 3.2 MICs (µg/ml), Plasmid Profiles (Kb) and Genes found in representative isolates collected in 2007 
2007 AMC CARB P/T CTHIN CRO CTX CAZ CROX AMP IMI AZT 
Plasmid 
Profiles (Kb) Gene/s 
KEH3409 0.125 256 0.125 256 128 256 16 64 128 0.5 16 154; 24; 3 
TEM 1, SHV 
1, SHV 11 
KEH1506 32 256 16 256 128 128 32 128 128 0.25 32 207 TEM 1, SHV 1  
KEH2924 16 256 16 256 64 32 32 32 128 0.5 16 207; 27 TEM 1, SHV1 
KEH3217 16 256 16 256 128 256 128 256 128 0.5 64 
207; 59.6; 27; 
7 
TEM 1, SHV 
1, SHV 11 
KEH893 16 256 16 256 16 64 16 32 128 0.125 8 110; 7 TEM 1, SHV 2 
KEH2786 32 256 32 256 128 128 8 128 128 0.125 16 
207; 24; 10; 4; 
1.7 
TEM 1, SHV 
11, CTX-M-15 
KEH3281 16 256 16 256 128 256 128 256 128 8 64 207; 154; 24 
TEM 1, SHV 
1, SHV 11 
KEH2605 2 256 0.125 256 128 128 16 128 128 0.125 32 207; 36 
TEM 1, SHV 
1, SHV 11 
KEH2787 16 256 16 256 128 128 8 128 128 0.125 16 207 
TEM 1, SHV 





Due to financial constraints, a comprehensive analysis of a wide range of enzymes was not 
possible therefore molecular detection of ESBLs were carried out using representative isolates 
from groups exhibiting similar phenotypic resistance profiles. This was done by grouping 
isolates according to the antibiotics they showed rsistance to using the MIC values. 
Sequencing was based largely on the phenotypic expression of the most common ESBL 
genes, however we included the less common blaOXA and blaDHA as MICs shown in tables 3.1 
and 3.2, gave indication of the presence of these gnes. The OXA-type β-lactamases confer 
resistance to ampicillin and cephalothin and are poorly inhibited by clavulanic acid (Bradford, 
2001). PCR yielded no positives for blaOXA, even though susceptibility results postulated  
their presence. This may be the result of the blaOXA genes being absent (Poirel, Naas and 
Nordmann, 2010).  Phenotypic tests for DHA β-lactamases were negative; however PCR for 
DHA was undertaken based on a study done by Roh, et al., (2008) who reported multi drug 
resistant K. pneumonia isolates harboring both SHV and DHA type ESBLs.PCR and 
sequencing yielded no positives for DHA β-lactamases.  
 
All isolates sequenced carried the genes encoding both the TEM and SHV β-lactamases.   
TEM – 1 was identified in all isolates and SHV-1 and SHV-2 were identified in 60 % in the 
isolates collected in 2000 and 77 % and 11 % respectively in the isolates collected in 2007. 
These results lead us to believe that there could be an anomaly with the strains in both 
collection periods as we did not have 100 % SHV-1 present.  Since every isolate did express 
an SHV gene, it was postulated that the SHV-1 gene may have been masked by another SHV 
gene that was preferentially amplified. The reduced susceptibility to amoxicillin-clavulanate 
and narrow-spectrum cephalosporins in many of the isolates from 2000, as explained by 
Dubois et al., (2008), could be due to the acquisition of plasmid-ediated broad-spectrum β-
lactamase or overproduction of the chromosomal enzyme of SHV-1.  
 
It has been well documented that blaSHV is present on the chromosome of nearly all K. 
pneumonia isolates (Turner et al., 2009)with the great majority possessing a chromosomal 
copy of either blaSHV-1 or blaSHV-11 or close relatives (Hammond et al., 2007). There has been 
strong evidence to suggest that blaSHV originated from the chromosome of K. pneumoniae and 
an IS26 element played a role in the mobilization of blaSHV from genome to plasmid (Harada 
et al., 2008)SHV – 11 was present in 67% of isolates from 2007 and 55% of those were in 
combination with SHV – 1.   Based on the phenotypic profiles we see in this study we 







According to the MICs in tables 3.1 and 3.2 respectiv ly we hypothesize that isolates KEH6 
and KEH21 from the 2000 isolates and KEH 2786 from 2007 follow the phenotypic profile of 
TEM-50. Studies by Sirot, et al., 1997 and Stapleton, Shannon and French, 1999 revealed that 
the phenotypic profile of TEM -50 displays resistance to Amoxicillin-Clavulanate (AMC) and 
piperacillin-tazobactam (P/T) and shows susceptibility to Cefotaxime (CTX), Ceftazidime 
(CAZ) and Aztreonam (AZT). It is possible that TEM-1 found in these isolates could have 
been preferentially amplified by PCR hence the TEM-50 could not be picked up.  
SHV-2 was found in 3 isolates in 2000 and 1 isolate in 2007. The phenotypic profiles of all 
these isolates however did not match each other accur tely. A study by Coque, et al., 2002 
revealed a number of different resistance profiles for SHV-2.  Many of the isolates were 
sensitive to cefotaxime, ceftazidime and aztreonam while others showed resistance for the 
same drugs. Due to this difference in resistance profiles, the authors suggest that plasmid 
dissemination may have facilitated the spread of the blaSHV-2 gene. The selection pressure 
from treatment of these antibiotics could have facilit ted the evolution of blaSHV-1 via mutation 
therefore producing a derivative that simultaneously harbors blaSHV-1 and blaSHV-2 (Coque, et 
al., 2002).  Sequencing revealed that isolate KEH2786 possesses CTXM-15; the resistance 
profile however showed an intermediate result to ceftazidime which is uncharacteristic for 
CTXM-15 as it usually confers high levels of resistance to ceftazidime.  A study by Poirel, 
Gniadkowski and Nordmann, (2002), revealed that CTXM-15 has a single amino acid change 
compared to CTXM-3 and analysis of their resistance profiles showed that CTXM-3 confers 
lower or intermediate levels of resistance to ceftazidime. This suggests that KEH 2786 could 
very well possess a CTXM-3 enzyme as is indicative by both its intermediate resistance to 
ceftazidime and the higher susceptibility to inhibition by tazobactam compared with 
clavulanic acid (Poirel, Gniadkowski and Nordmann, 2002). 
 
Isolate KEH3281 was the only isolate showing an intermediate result to imipenem, 
sequencing however did not reveal any KPC enzymes. Su ceptibility to imipenem is a 
positive finding in this population as the recognition of carbapenemase expression is the key 
to appropriate treatment of carbapenem resistant enterobacteriacae. However, due to 
heterogeneous expression of resistance, it creates difficulties in ascertaining carbapenem 
resistance  (Brink et al., 2012).  All of the isolates tested in 2000 and 2007 showed high 
levels of resistance to carbenicillin which is indicat ve of the CARB-3 enzyme. At the time of 
sequencing, however CARB-3 was not included in the list of enzymes but based on the 






A study by Okesola and Makanjuola, (2009) revealed that poor susceptibility to 
amoxicillin/clavulanate of the isolates in that environment demonstrates a high probability of 
the production of new β-lactamases. Inhibitor resistant TEM β-lactamases (IRTs) have been 
reported globally in many different organisms.  IRT-producing isolates remain susceptible to 
cephalosporins, cephamycins, carbapenems, and in most cases are intermediate or resistant to 
amoxicillin-clavulanate combinations (Martín et al., 2010). IRTs have been reported by 
Martín et al., (2010) in E. coli isolates with a high degree of IRT diversity. A study done by 
Mocktar et al., (2009) revealed the presence of two IRT enzymes, viz. TEM 145 and TEM 
146 in E. coli isolates. It was suggested that single or multiple mutations in the structural 
genes of β-lactamases may have facilitated the emergence of inhibitor resistant enzymes 
(Mocktar et al., 2009). 
 
In this study, sequencing did not reveal the presence of IRTs. The resistance profiles however 
do give us an indication of TEM-50 but this phenotypic approach to the detection of IRTS 
may have limitations due to the inconsistency of the IRT phenotype (Martín et al., 2010). The 
presence of other resistance mechanisms such as theTEM-1 and the combination of multiple 
β-lactamases can often render strains resistant to the β-lactam-β-lactamase inhibitor 
combinations (Bradford et al., 2004). The IRT phenotype can be masked by the preferential 
amplification and subsequent sequencing of one enzyme, in this case TEM-1. The absence of 
chromatograms also creates difficulty in ascertaining the presence of these enzymes. 
Substitutions in the promoter region of the IRT gene coding region also may affect the 
expression of IRT enzymes thus affecting the selection of IRT producing isolates (Canton et 
al., 2008).  The poor susceptibility to amoxycillin/clavulanate, 6% in 2000 and 33% in 2007 
in these two populations could very well indicate the presence of IRTs, however further 
studies would provide further information in support of that hypothesis. 
 
Plasmids have been important contributors to the rapid cquisition of antibiotic resistance by 
pathogenic bacteria through their ability to acquire resistance genetic determinants and to 
transfer them among bacteria belonging to the same or different genera and species (Bistue et 
al., 2008). These resistance genes which are usually located inside transposable elements, 
integrons and insertion sequences (IS) help to facilitate their mobility. The plasmid profiles of 
the isolates in this study showed extensive diversity and the plasmid banding patterns did not 
match the resistance profiles of isolates within the same group.  Studies have shown that 
members of a single epidemic strain may carry different plasmids and genotypically non-
related strains can produce the same ESBL due to plasmid transfer between species (Paterson 
and Bonomo, 2005; Bauerfiend et al., 1996 and Fiett et al., 2000).  Genes for antibiotic 





plasmids are conjugative as it allows pathogenicity and resistance genes to disseminate across 
strains, species and even genera (Yi et al., 2010).   Independent evolution due to antibiotic 
pressure plays a role as well as it has been evident that different plasmids have the ability to 
mediate the same ESBL (Paterson and Bonomo, 2005; Bradford, 2001). Resistance has 
increased from 2000 to 2007 with the isolates tested in this study; the banding patterns from 
2007 shows a slightly higher genetic diversity which ould be the reason for the higher 
resistance in this population.  Zhao et al., (2010) reported an increase in multi-drug resistance 
in isolates collected over two time frames, the isolates collected from the later time showed a 
remarkable increase in MDR with a high genetic diversity in the plasmids of the K pneumonia 
strains collected. The authors suggest that bacteri st engthen their antibiotic resistance by 
frequently exchanging multi-resistance plasmids andby having elevated mutation rates in 
their plasmids.  A high copy number of antibiotic resistance genes have also been attributed to 
a high level of MDR; integrons have the power to assemble resistance genes in a correct 
orientation to supply a strong promoter for the expr ssion of these genes (Zhao et al., 2010; 
Nikaido, 2009).  The high mutation rate in plasmids a  well as the widespread gene 
duplication or loss, or lateral gene transfer in the plasmids is an important factor to consider in 
multi-drug resistance (Zhao et al., 2010). 
 
 Vaidya, (2011) reported several cases of multi drug esistant E. coli and K. pneumonia 
(MDR-EK) in various studies that showed no link betw en MDR and previous exposure to 
antibiotics. Rodrigues et al., (2005) reported a case of 100 healthy executives receiving a 
routine check-up in Mumbai showed the presence of 11% of ESBL producing E. coli and K. 
pneumonia with none of them having been admitted in hospital or having received any 
antibiotic therapy in the last six months before testing. This is indicative of the role that 
plasmids play in antibiotic resistance. When the sel ction pressure of antibiotics is exerted, 
bacteria already have a large population of resistance genes available to them and this creates 
an ongoing spread of antibiotic resistance (Vaidya, 2011). 
 
3.2 Antibiotic use and resistance 
 
The introduction of antibiotics into modern medicine has been a very important stepping 
stone in attempting to circumvent the rate of mortality due to nosocomial infections; however 
the intensive use of antibiotics has only served to increase the frequency of resistance among 
many pathogens to date (Andersson and Hughes, 2010).  Several studies, as reported by 
Hawkey, (2008) and Andersson and Hughes, (2010) have in estigated the effect of the 





studies demonstrated the effectiveness of antibiotic restriction and an increase in 
susceptibility however such investigations were carried over 12 or more years.  
 
 
Table 3.3 shows the change in susceptibility for 2000 and 2007 as well as the change in 
antibiotic use. Susceptibility decreased between 2000 and 2007 in eight of the drugs that we 
tested.  Three of the drugs tested, viz.  ampicillin, piperacillin sodium injection and 
gentamicin injection showed no susceptibility in both years.  There was only one drug, 
piperacillin/tazobactam injection where susceptibili y increased.  The median susceptibility 
decreased significantly between the two years from 0.5 in the year 2000 to 0.055 in the year 
2007, p =0.01 (Table 3.4) 
 
Increase in antibiotic resistance has been largely attributed to the overuse of antimicrobials as 
well as the transfer of resistance genes via plasmids. The results in table 3.3 indicates that the 
overall antibiotic use has decreased in 2007 however the susceptibility has decreased. There 
are other factors to consider in the decrease in susceptibility; firstly, infection control; there 
are strict prevention and infection control guidelin s that are to be implemented in hospital 
and health care settings. The guidelines strictly promote hand hygiene with health care 
workers when dealing with patients and their environments as well as implementing patient 
contact precautions for infected patients (Sydnor ad Perl, 2011).  
Table 3.3 The change in overall antibiotic use and susceptibility between 2000 and 
2007 
Antibiotic Use Susceptibility 
Antibiotic 2000 2007 change 2000 2007 change 
       Ampicillin  0.009 0.002 -0.07 0 0 0 
Piperacillin sodium injection 0.001 0.001 0.0001 0 0 0 
Pipracillin/tazobactam injection 0.097 0 -0.097 80 89 9 
Amoxicillin -clavulanate 0.973 0.071 -0.902 40 26 -14 
Cefuroxime Sodium Injection 0.043 0.024 -0.019 20 0 -20 
Cefotaxime Injection 0.006 0.0059 -0.0001 60 0 -60 
Ceftazidime Injection 0 0.0002 0.0002 100 11 -89 
Amikacin Injection 0.009 0.013 0.004 100 95 -5 
Gentamicin injection 0.001 0 -0.001 0 0 0 
Nalidixic acid tablets 0.008 0.001 -0.007 60 11 -49 
Ceftriaxone 0.016 0.064 0.048 20 0 -20 





In such settings the compliance to adhere to such measures may be poor which undermines 
the usefulness of such measures.  Owens and Rice, (2006) described various studies which 
report failure to adhere to infection control policies and the ramifications of such non-
compliance which ultimately lead to the dissemination of resistant pathogens.  
 
Such infection control strategies apply to clinical l boratories as well where protocols 
consistent with CLSI guidelines should be followed with respect to the detection of infectious 
organisms.  Hospitalized patients often undergo certain procedures and invasive 
manipulations which contribute to colonization and infection with ESBL producing 
organisms. Pfaller and Segreti, (2006), report a case-control study designed to identify risk 
factors in acquiring ESBL producing K. pneumonia. They reported that a tracheostomy and 
the insertion of a Foley catheter, endotracheal tube, nasogastric tube and a central venous 
catheter were all associated with infection with ESBL-producing K. pneumonia. The 
association was made based on the assumption that patients requiring such invasive 
manipulations require a longer stay in hospital which renders them susceptible to resistant 
pathogens.  Pena et al., (2001) also reported a case of ICU patients where the infection of 
ESBL K pneumonia was much higher than non-ESBL K. pneumonia (96% vs. 46%) due to 
ICU patients undergoing a larger number of invasive procedures therefore the risk of 
inappropriate catheter manipulation being greater.  Another important factor to consider is 
surveillance with respect to supply and rational use. In many countries where healthcare is not 
easily accessible or affordable, many patients seek th  assistance of medicine dispensaries 
whereby self medication without prescription is very common. Surveillance measures need to 
be put into place for the rational use and availabil ty of antimicrobials. 
 
  
Antibiotic use increased for 4 drugs, viz. amikacin ,  ceftriaxone, ceftazidime and piperacillin 
sodium and decreased for the remaining 8 drugs   The median use in the year 2000 was 
slightly higher (median = 0.009) when compared to the year 2007 (median = 0.004) but the 
difference did not reach statistical significance, p = 0.12. 
 






n median IQR n median IQR p value* 
Antibiotic Use 12 0.009 (0.0035 - 0.0375) 12 0.004 (0.0006 - 0.0225) 0.12 
Susceptibility 12 0.5 (0.1 - 0.8) 12 0.055 (0 - 0.185) 0.01 
* using wilcoxon signed rank test 





Many studies could not conclusively provide evidence for an increase in susceptibility despite 
restricted use of antibiotics and showed still a decrease in susceptibility. With respect to the 
isolates that were tested in this study, we see a decrease in susceptibility.  This can be 
attributed to the horizontal gene transfer mechanisms mentioned earlier, which microbes 
make use of  to acquire resistance as well as the selective pressure of the antibiotics being 
used in the time frame between the collection dates of the isolates. Further investigation into 
this may provide additional evidence to prove the hypothesis with respect to populations in 
Kwa-Zulu Natal state hospitals. 
 
Table 3.5 The change in grouped Antibiotic Use and Susceptibility for 2000 and 2007 
  Antibiotic Use Susceptibility 
Antibiotic 2000 2007 change 2000 2007 change 
Decrease in susceptibility 
   
  
  Increased Antibiotic Use 
   
  
  Amikacin Injection 0.009 0.013 0.004 100 95 5 
Ceftriaxone 0.016 0.064 0.048 20 0 20 
Ceftazidime Injection 0 0.0002 0.0002 100 11 89 
    
  
  Decreased Antibiotic Use 
   
  
  Amoxicillin -clavulanate 0.973 0.071 -0.9021 40 26 14 
Nalidixic acid tablets 0.008 0.001 -0.0072 60 11 49 
Ciprofloxacin 0.032 0.026 -0.006 80 11 69 
Cefuroxime Sodium Injection 0.043 0.024 -0.0189 20 0 20 
Cefotaxime Injection 0.006 0.006 -0.0001 60 0 60 
    
  
  No decrease in susceptibility 
  
  
  Increased Antibiotic Use 
   
  
  Piperacillin sodium injection 0.001 0.0011 0.0001 0 0 0 
    
  
  Decreased Antibiotic Use 
   
  
  Piperacillin/tazobactam 
injection 0.097 0 -0.097 80 89 -9 
Ampicillin  0.009 0.002 -0.0069 0 0 0 








Table 3.5 shows the comparison of antibiotic use versus susceptibility in groups. The drugs 
were divided into two groups, those that showed a decrease in susceptibility (n = 8) and those 
that did not (n = 4).  The change in antibiotic usebetween the years 2000 and 2007 was then 
calculated for each group in order to determine if change in use differed in the two groups. 
The change in use for drugs showing no change in susceptibility (median =0.0038) was 
similar to the change in use for drugs showing a decrease in susceptibility, (median = 0.0035), 
p = 0.2 (Table 3.6). This lead us to believe that tere is co-carriage of resistance genes in the 
isolates that were tested. 
 
For more than two decades, there have been reports on outbreaks caused by gram negative 
bacilli containing ESBLs and their resistance to cephalosporins as well as other β-lactam 
antibiotics (Medeiros, 1997). A study by Wiener t al., 1999 uncovered an outbreak in 
American nursing homes of ceftazidime resistant K. pneumonia and E. coli. The authors 
reported that infection with those strains were most often not linked with ceftazidime use and 
it was possible that the use of trimethoprim-sulfamethoxazole may have selected for 
ceftazidime-resistant strains because of plasmid linkage of the resistance determinants for 
these drugs.  A later study by Sahm et al., (2001) also reported fluoroquinolone resistance 
with considerably high levels of ceftazidime resistance in the same isolates.  
 
It has been evident that quinolone resistance was the result of mutations in chromosomal 
genes coding for targets of quinolone action. However, frequent co-existence of ESBL 
production and quinolone resistance had been noted (Paterson et al., 2004). Table 3.3 shows 
evidence of this with the increase in resistance to ceftazidime as well as to the 
fluoroquinolones with an increase in ceftazidime use but a decrease in fluoroquinolones.  
Hawkey and Jones, (2009), reported that it is possible that low level plasmid-encoded 
fluoroquinolone resistance has provided a selective advantage for bacteria exposed to 
fluoroquinolones to allow the easier selection of high-level resistance mutations in the Gyrase 
subunit gyrA, thus explaining the association of chromosomal quinolone resistance with 
plasmid-encoded ESBL genes. 
Table 3.6 Wilcoxon signed rank test for the grouped antibiotic use and susceptibility in 2000 
and 2007. 
Susceptibility n median IQR p value* 
No change 4 0.0038 (0.003-0.052) 
 Decrease 8 0.0035 (-0.0006 - 0.0151) 0.23 
Total 12 0.0038 (-0.001 - 0.0151)   





An organism that is resistant to multiple drugs is more susceptible to selection by the 
exposure to even one of those drugs as is evident in our study. Tumbarello et al., (2006) 
showed significant evidence of this in their population where 50% of the isolates were 
resistant to fluoroquinolones and were from patients who had been previously undergone 
antimicrobial treatment.  A study by Schwaber et al., (2005), tested four of the most common 
Enterobacteriaceae against ciprofloxacin, gentamicin, amikacin, piperacillin/tazobactam, 
trimethoprim-sulfamethoxazole and imipenem to compare antimicrobial co-resistance 
between ESBL producing and non-ESBL producing isolates. High levels of co-resistance 
were observed (≥ 40%), to all agents with the exception of amikacin and imipenem, in the 
ESBL producers. The authors suggested that this co-resistance could be a result of 
transferable elements that confer resistance to antimicrobials other than β-lactams and travel 
on or alongside ESBL-containing plasmids yielding multi-drug resistant bacteria.  Table 3.7 
shows the MIC values of the aminoglycosides and fluoroquinolones tested in this study. 
Many of the isolates collected in 2007 have shown decreased susceptibility to 
aminoglycosides and fluoroquinolones.  
 
With respect to the resistance to aminoglycosides and fluoroquinolones as well as the 
resistance to 3rd generation cephalosporins, this study has confirmed th  presence of multi-
















































Figure 3.2 is an illustrative comparison of the increase in resistance to aminoglycosides and 
fluoroquinolones between the two collection periods. Due to resistance being carried on a 
variety of resistance determinants that may be integra d on plasmids of different sizes, this 
creates difficulty in curbing the spread of resistance by just controlling the use of 
antimicrobials. 
 
Table 3.7 MIC values (µg/ml)  for aminoglycosides and fluoroquinolones 
tested for both collection dates. 
2000 Amikacin Ciprofloxacin Gentamicin 
Nalidixic 
Acid 
KEH6 0.25 0.125 64 8 
KEH3 0.5 0.06 64 8 
KEH100 0.25 0.125 64 128 
KEH21 0.25 0.03 64 8 
KEH81 0.5 4 64 128 
2007 Amikacin Ciprofloxacin Gentamicin 
Nalidixic 
Acid 
KEH1506 2 16 64 128 
KEH893 2 4 64 16 
KEH2605 4 16 64 128 
KEH2787 4 16 64 128 
KEH2786 2 16 64 128 
KEH2924 1 0.25 64 128 
KEH3217 8 32 64 128 
KEH3281 32 32 64 32 





Figure 3.2 Illustration of the increase in resistance to aminoglycosides and fluoroquinolones 
over the two collection periods  
 
Various modes of dissemination of MDR has been described and attributed to plasmid spread 
and gene transfer via integrons however it is very likely that dissemination does occur as a 
result of antibiotic selection pressure (Wener et al., 2010).  There have been reports from a 
few studies which suggest a positive association between antimicrobial consumption and 
bacterial resistance, however there are many studie that claim that these associations are not 
evident. The association between antibiotic consumption and resistance is frequently seen at a 
patient level in case control studies, and also at a hospital and community level, the same 
relationship can be seen with susceptibility where the reduced use of one agent is associated 
with increased use of another (Gould, 2009).  A study by Bergman et al., (2009) investigated 
the association between antimicrobial resistance and consumption. There was no direct 
correlation between resistance and overall consumption but they did report a few significant 
relationships between resistance and certain antimicrobials such as nitrofurantoin use and 
nitrofurantoin resistance as well as amoxicillin use and fluoroquinolone resistance. There was 
however no correlation between fluoroquinolone use and fluoroquinolone resistance. A study 
by van de Sande-Bruinsman et al., (2008), however did find a strong correlation between 
fluoroquinolone use and fluoroquinolone resistance which they attribute to mutations in the 
chromosomal genes resulting in a modification of the molecular target which eventually leads 







A study undertaken by Hsu et al., (2010) reported no significant correlation between 
antimicrobial use and resistance. One of the reasons suggested by the author was the 
limitation of using the DDD for antibiotic use data.  Resistance selection pressure occurs at 
the individual level and the DDD does not take into account the individual exposure to 
antimicrobial treatment as it will vary from patient to patient. It is mainly patients who are 
susceptible to drug resistant pathogens that receiv broad spectrum antibiotics therefore the 
DDD presents inherent biases based on the factors taken into account to calculate DDD (Hsu 
et al., 2010).   A study by Lai et al., (2011) reported non-uniform relationships with the usage 
and resistance in their bacterial isolates which was monitored in various hospitals over a 
period of ten years. The suggested reasons had been th  limitation of using the DDD as well 
as the co-resistance between different classes of antibiotics that were not taken into account. 
 
In light of both arguments however, emphasis must be placed on the rational and sensible use 
of all antimicrobial agents. It is imperative that antibiotic consumption and the relative rate of 
antimicrobial resistance are monitored. Infection control measures in hospitals and in the 
community need to be monitored and strict compliance should be implemented in order to 
reduce the dissemination of these resistance strain.  There needs to be specific attention paid 
to the accurate detection of ESBL producers, their tr atment strategies and infection control 





























Many researchers have stressed that bacteria are thought to have evolved 3500 billion years 
ago and the use of antimicrobials have only been put into effect for about 60 years now, thus 
leading to the argument that bacteria such as K. pneumonia have had more time to adapt to 
the various conditions in their environment. It has been said by Spellburg et al, (2008) that 
their genetic plasticity and the rapid rate of their replication has given bacteria an 
immeasurable advantage over even modern medicines con tant attempts to curtail the 
problem of increasing resistance. 
 
The two small bacterial populations in this investiga on along with numerous studies done 
over many years provide proof to this claim. There has been a decrease in susceptibility over 
the two time frames and although there were no novel β-lactamases identified in this study, 
we have identified a trend with a decrease in susceptibility over time further proving bacterial 
evolution.  This study presented us with a variety of β-lactamases and a diversity of plasmid 
profiles and by extension genetic determinants in which they appear to reside has 
demonstrated the ease of dissemination.    
 
Improvements in prescribing β-lactams has been recommended as a way to reduce the hig  
levels of resistance over the years, however, in this study it was observed that resistance 
increased despite only a slight increase in the use of a few antibiotics to which we attributed 
co-carriage of resistance genes. It is certainly advantageous to use antibiotics only when 
suitable, to try to limit the selective pressure that increases the frequency of resistance. On the 
other hand, a distinction between an increase in antibiotic usage causing the increase in 
bacterial resistance or the rate at which resistance spreads (Andersson and Hughes, 2010; 














The full gamut of potential genetic determinants of resistance such as integrons, gene 
cassettes and insertion sequences were not investigated. 
Definitive identification of ESBLs were restricted to a few classes because of financial 
constraints and the full range of putative ESBLs were thus not investigated. 
The acquisition of control strains was precluded by financial constraints 
 
4.3 Further Studies 
 
PCR and sequencing have proven to very complex and expensive in routine genotypic 
detection of ESBL genes. High Resolution Melt Analysis (HRMA), a fairly recent technique 
is a simple solution for genotyping, mutation scanning as well sequence matching (Reed et al, 
2007). HRMA is being increasingly applied to identify resistance mutations in various 
organisms with a wide range of antimicrobials (Hidalgo-Grass and Strahilevitz, 2010). The 




























1. 1M Tris Solution pH 7.0 
To make 1 litre:  
• 121.1 g Tris base  
• 800 ml sterile distilled water   
• Dissolve Tris in sterile distilled water and adjust the pH with concentrated HCl:  
• Bring to 1 litre with sterile distilled water 
 
2. Sodium Dodecyl Sulphate (SDS) solution 
A 6% SDS solution was prepared as follows: 
• 6g of Sodium dodecyl sulphate (Sigma Aldrich) 
• 100ml Sterile distilled water 
 
3. 10X TE (Tris-EDTA) Buffer 
To make 1 litre: 
• 100 ml 1 M Tris-HCl pH 7.5  
• 20 ml 500 mM EDTA pH 8.0 (Fluka) 
• 880 ml sterile distilled water  
 
4. 10X TAE Buffer 
To make 1 litre: 
• 48.4 g of Tris base [tris(hydroxymethyl)aminomethane]  
• 11.4 mL of glacial acetic acid (17.4 M)  
• 3.7 g of EDTA 
• Sterile distilled water 
 
5. 50 mM Tris: 3% SDS solution 
• Equal volumes of 50mMtris(hydroxymethyl)aminomethane solution and sodium 
dodecyl sulphate solution were mixed to yield a final solution of 50 mM tris 
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